



**HAL**  
open science

## **NKX2-5: An Update on this Hypermutable Homeodomain Protein and its Role in Human Congenital Heart Disease (CHD)**

Stella Marie Reamon-Buettner, Juergen T Borlak

► **To cite this version:**

Stella Marie Reamon-Buettner, Juergen T Borlak. NKX2-5: An Update on this Hypermutable Homeodomain Protein and its Role in Human Congenital Heart Disease (CHD). *Human Mutation*, 2010, 31 (11), pp.1185. 10.1002/humu.21345 . hal-00585168

**HAL Id: hal-00585168**

**<https://hal.science/hal-00585168>**

Submitted on 12 Apr 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**NKX2-5: An Update on this Hypermutable Homeodomain Protein and its Role in Human Congenital Heart Disease (CHD)**

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0256.R1
Wiley - Manuscript type:	Review
Date Submitted by the Author:	15-Jul-2010
Complete List of Authors:	Reamon-Buettner, Stella Marie; Fraunhofer Institute of Toxicology and Experimental Medicine, Molecular Medicine and Medical Biotechnology Borlak, Juergen; Fraunhofer Institute of Toxicology and Experimental Medicine, Molecular Medicine and Medical Biotechnology
Key Words:	heart development, congenital heart disease, cardiac malformations, transcription factors, NKX2-5, mutations

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **NKX2-5: An Update on this Hypermutable Homeodomain Protein and its Role in Human Congenital Heart Disease (CHD)**

Stella Marie Reamon-Buettner and Juergen Borlak\*

Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and  
Experimental Medicine, Nikolai-Fuchs-Strasse 1, D-30625 Hannover, Germany.

\*Correspondence to Prof. Dr. Juergen Borlak, Molecular Medicine and Medical  
Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Nikolai-  
Fuchs-Strasse 1, 30625 Hannover, Germany.

Tel: +49-511-5350-559; Fax +49-511-5350-573; E-mail: borlak@item.fraunhofer.de

Contract grant sponsors: Ministry of Science and Culture, Lower Saxony, Germany; Contract  
grant number: 25A.5-76251-99-3/00

**ABSTRACT**

Congenital heart disease (CHD) is among the most prevalent and fatal of all birth defects.

Deciphering its causes, however, is complicated as many patients affected by CHD have no family history of the disease. There is also widespread heterogeneity of cardiac malformations

among affected individuals. Nonetheless, there have been tremendous efforts towards a better understanding of the molecular and cellular events leading to CHD. Notably, certain cardiac-

specific transcription factors have been implicated in mammalian heart development and

disruption of their activity has been demonstrated in CHD. The homeodomain transcription factor *NKX2-5* is an important member of this group. Indeed, more than 40 heterozygous

*NKX2-5* germline mutations have been observed in individuals with CHD and these are

spread along the coding region, with many shown to impact protein function. Thus, *NKX2-5*

appears to be hypermutable (?) highly mutable, yet the overall detection frequency in sporadic

CHD is about 2% and *NKX2-5* mutations are one-time detections with single-positives or

private to families. Furthermore, there is lack of genotype-phenotype correlation, in which the

same cardiac malformations have been exhibited in different *NKX2-5* mutations or the same

*NKX2-5* mutation associated with diverse malformations. Here, we summarize published

*NKX2-5* germline mutations and explore different avenues in disease pathogenesis to support

the notion of a multifactorial cause of CHD where possibly several genes and associated

pathways are involved.

**Keywords:** heart development, congenital heart disease, cardiac malformations, transcription factors, *NKX2-5*, mutations

Deleted: within

Deleted: in CHD; foremost is

Deleted: t

Deleted: -----Page Break-----

¶

Formatted: Don't adjust right indent when grid is defined, Line spacing: Double, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

1  
2  
3 Dr. Mark Paalman  
4 The Managing Editor  
5 Human Mutation  
6

7  
8 Dear Dr. Paalman:  
9

10 Many thanks for the encouraging news on our manuscript " NKX2-5: An Update on this  
11 Hypermutable Homeodomain Protein and its Role in Human Congenital Heart Disease (CHD)"  
12 Human Mutation Paper No. humu-2010-0256. Attached is the revised manuscript, as well as the  
13 response to the managing editor's comments.  
14

15  
16  
17 We look forward to seeing our work published in Human Mutation.  
18

19  
20 Sincerely yours,  
21

22 JUERGEN BORLAK  
23  
24  
25  
26

### 27 **RESPONSE TO MANAGING EDITOR'S COMMENTS**

28  
29  
30 1) The mutation nomenclature appears to follow the format indicated in the  
31 Author Instructions (see the website <http://www.hgvs.org/mutnomen/> and also  
32 the nomenclature checklist at <http://www.hgvs.org/mutnomen/checklist.html>).  
33 Things to watch for:

34 a-Mention the GenBank reference sequence and version number for the gene(s)  
35 studied (i.e., include the decimal point following the accession number in the  
36 sequence record) in the Materials and Methods and as a footnote to the  
37 relevant tables and figure.

38  
39 b-Clearly indicate in the Methods text and tables that the DNA mutation  
40 numbering system you use is based on cDNA sequence. Explanatory text is  
41 required in legends and text, for example:

42 "Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A  
43 of the ATG translation initiation codon in the reference sequence, according  
44 to journal guidelines ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)). The initiation codon is codon  
45 1."

### 46 **RESPONSE :**

47 *The footnote below is incorporated in Table 1, Supp.Tables S2 and S3.*

48  
49  
50 *"Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation  
51 codon in the reference sequence NM\_0004387.3, according to journal guidelines ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)). The  
52 initiation codon is codon 1. "*

53  
54 c-Authors are advised to check sequence variant descriptions using the  
55 Mutalyzer program  
56 (<http://www.LOVD.nl/mutalyzer/>) - using batch mode, all variants for a gene  
57 can be analyzed at once. See the article Wildeman et al. Hum Mutat 29, 6-13,  
58 2008 <http://www3.interscience.wiley.com/cgi-bin/fulltext/116842325/PDFSTART>  
59  
60

**RESPONSE :**

*The batch mode of Mutalyzer was used to check the list of NKX2-5 mutations.*

d-All authors should verify that the mutations reported (especially novel ones) have been or will be submitted to an existing locus-specific database for the genes involved. Visit the HGVS-LSDB list to search for databases: <http://www.hgvs.org/dblist/glsdb.html>

**RESPONSE :**

*Review paper, and no novel mutations being reported.*

2) On resubmission:

a-Please double check the author names and affiliations carefully. These are often a source of typographical errors.

**RESPONSE :**

*Authors' names and affiliations checked.*

b-Title Page, Abstract (180-200 words max), Key Words, Main Text, References, and Figure Legends should be combined into one file for the manuscript and submitted as a \*.doc file.

**RESPONSE :**

*The submitted\*.doc. file (NKX2-5 humu10-0256\_text.doc) contains the specified components; Abstract is 200 words.*

c-Figures for main article must be submitted as separate files with high resolution (at least 200 dpi) as \*.tif or \*.eps format only.

--For color figures in print: submit two files for each color figure: one in CMYK color space and one in RGB color space (with the true color you wish to have published). If you cannot provide CMYK color e-files for the print version, please let me know.

**RESPONSE :**

*Figure3 is 200 dpi, the rest are 300 dpi; both CMYK and RGB files for Figure 3 and Figure 4.*

d-Tables must be submitted individually as separate \*.doc files (with their titles and legends included). Please use the MS Word table format if possible. Excel (\*.xls) files should not be submitted.

--Do not use custom paper sizes - only use Letter or A4.

**RESPONSE :**

*Table 1. Functional Consequences of Identified NKX2-5 Mutations in CHD: Functional Assays or Bioinformatic Analysis is contained in \*.doc.file NKX2-5 humu10-0256\_Table 1.doc.*

*Table 2. Detection Frequency of NKX2-5 Germline Mutations in Congenital Heart Disease is contained in \*.doc.file NKX2-5 humu10-0256\_Table 2.doc.*

e-Any Supporting Tables or Figures should be named and cited from the text as follows: 'Supp. Table S1' and 'Supp. Figure S1' (see below).

--If possible, do not use custom paper sizes - Letter or A4 are preferred.

**RESPONSE :**

*As instructed Supplementary Materials are named in the text accordingly.*

1  
2  
3 f-Supporting Figures and Tables should be prepared in a single MS Word \*.doc  
4 file labeled 'Supp\_Mat', with Figures preceding Tables. Each table/figure  
5 should be accompanied with its legend.  
6

7 **RESPONSE :**

8 *The single file NKX2-5 humu10-0256\_Supp\_Mat.doc contains the following:*

9 ***Supp. Figure S1. Geographical distribution of germline NKX2-5 mutations in CHD along the***  
10 ***coding sequence of the gene; Supp. Table S1. Studies on NKX2-5 Mutations Associated with***  
11 ***Congenital Heart Disease (CHD); Supp. Table S2. Summary of Published Germline NKX2-5***  
12 ***Mutations in Patients with Congenital Heart Defects; Supp. Table S3. Functional Significance of***  
13 ***Published Germline NKX2-5 Mutations in Patients with Congenital Heart Disease***  
14  
15

16  
17 3) Please check to see that the references follow the journal's standard  
18 format and are cited properly. All authors must be listed, for example. See  
19 our online Author Instructions [http://www3.interscience.wiley.com/cgi-](http://www3.interscience.wiley.com/cgi-bin/jabout/38515/ForAuthors.html)  
20 [bin/jabout/38515/ForAuthors.html](http://www3.interscience.wiley.com/cgi-bin/jabout/38515/ForAuthors.html)  
21

22 **RESPONSE :**

23 *References are according to journal's format and updated to the latest status of publication.*

24 4) Figures 3 and 4 require color in the print version in order to be fully  
25 understood. We will offer you one free color print page. I think that both  
26 figures should fit on one color page. If any additional color is needed or  
27 desired, it would cost \$500 per page.  
28

29 **RESPONSE :**

30 *We are amenable to this suggestion, and many thanks for your offer of one free color print page.*  
31  
32

33 5) Human Mutation can accommodate researchers funded by agencies requiring  
34 open access publication. More information on Wiley-Blackwell's policy is  
35 available at:  
36 <http://www.interscience.wiley.com/openaccess>  
37

38 6) IMPORTANT INFORMATION REGARDING PREPRINTS

39 a-Human Mutation is now publishing online preprints of accepted manuscripts  
40 prior to typesetting and page proof corrections. It is therefore crucial that  
41 you revise your manuscript carefully so that errors (typographical and  
42 grammatical) are corrected BEFORE the final accepted manuscript is posted  
43 online. The accepted preprint version will remain online until the corrected  
44 proofs are received and the typeset manuscript is finalized. At that time, the  
45 preprint version will be replaced with the final, typeset version online, in  
46 Early View.

47 **RESPONSE :**

48 *We proofread the revised manuscript carefully, and no substantial changes carried out except for*  
49 ***some minor style editing (e.g. abstract), and updating of citations and references (e.g. Rauch et***  
50 ***al., 2010, De Luca et. al 2010).***  
51  
52

53 b-It is essential that you submit a copyright transfer agreement (CTA) upon  
54 submission of your revised manuscript. This will avoid delay in publication of  
55 your article upon acceptance. If possible, the CTA must be signed by the  
56 corresponding author and should be signed by all contributing authors if  
57 practical. All authors must be made aware of the CTA and the rights it conveys  
58 to them.

59 The CTA can be found here:  
60 [www.wiley.com/go/ctaus](http://www.wiley.com/go/ctaus)

1  
2  
3 and must be filled out completely, including the article title and manuscript  
4 number. Please fax it to this number: (201) 748-6091.

5  
6 **RESPONSE :**

7 *A signed CTA has been prepared and will be faxed to the above indicated number,*  
8 *as soon as the revised manuscript has been uploaded.*  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

1  
2  
3 **NKX2-5: An Update on this Hypermutable Homeodomain Protein**  
4  
5  
6 **and its Role in Human Congenital Heart Disease (CHD)**  
7  
8  
9

10  
11 Stella Marie Reamon-Buettner and Juergen Borlak\*

12  
13  
14  
15  
16  
17  
18  
19 Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and  
20  
21 Experimental Medicine, Nikolai-Fuchs-Strasse 1, D-30625 Hannover, Germany.  
22  
23  
24  
25  
26  
27  
28  
29

30 \*Correspondence to Prof. Dr. Juergen Borlak, Molecular Medicine and Medical  
31  
32 Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Nikolai-  
33  
34 Fuchs-Strasse 1, 30625 Hannover, Germany.  
35  
36

37 Tel: +49-511-5350-559; Fax +49-511-5350-573; E-mail: borlak@item.fraunhofer.de  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Contract grant sponsors: Ministry of Science and Culture, Lower Saxony, Germany; Contract  
48  
49 grant number: 25A.5-76251-99-3/00  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

Congenital heart disease (CHD) is among the most prevalent and fatal of all birth defects. Deciphering its causes, however, is complicated as many patients affected by CHD have no family history of the disease. There is also widespread heterogeneity of cardiac malformations within affected individuals. Nonetheless, there have been tremendous efforts towards a better understanding of the molecular and cellular events leading to CHD. Notably, certain cardiac-specific transcription factors have been implicated in mammalian heart development and disruption of their activity in CHD; foremost is the homeodomain transcription factor *NKX2-5*. Indeed, more than 40 heterozygous *NKX2-5* germline mutations are spread along the coding region, many impact protein function. Thus, *NKX2-5* appears to be hypermutable, yet the overall detection frequency in sporadic CHD is about 2% and *NKX2-5* mutations are one-time detections with single-positives or private to families. Furthermore, there is lack of genotype-phenotype correlation, in which the same cardiac malformations have been exhibited in different *NKX2-5* mutations or the same *NKX2-5* mutation associated with diverse malformations. Here, we summarize published *NKX2-5* germline mutations and explore different avenues in disease pathogenesis to support the notion of a multifactorial cause of CHD where possibly several genes and associated pathways are involved.

**Keywords:** heart development, congenital heart disease, cardiac malformations, transcription factors, *NKX2-5*, mutations

## Introduction

Cardiac malformations in congenital heart disease (CHD) result from errors during heart development, a process which is very complex and completed in a relatively short period of time. Essentially within eight weeks of embryogenesis, the human heart undergoes several stages of development involving cardiac crescent formation, linear heart tube formation, cardiac looping, chamber formation and maturation, septation and valve formation. At the molecular and cellular levels, heart development entails precise orchestration of genetic events, as well as the interplay of master transcriptional regulators, signaling pathways and chromatin remodeling rendering the understanding of CHD a challenging task. But great efforts are underway towards the unravelling of mechanisms leading to CHD, as conveyed in recent reviews (Bruneau, 2008;Nemer, 2008;Joziassse et al., 2008;Bajolle et al., 2009;Leong et al., 2009;Combs and Yutzey, 2009). Notably, the pivotal role of certain transcription factors in heart development has been demonstrated, and gene targeting of cardiac-specific transcription factor genes in animal models especially in mice has provided valuable insights into heart anomalies (Nemer, 2008).

Over the years, family-based studies identified mutations in several genes controlling heart development, especially transcription factor genes (see reviews, Clark et al., 2006; Bruneau, 2008;Benson, 2010). Among these transcription factor genes with mutations associated with human CHD include *NKX2-5* (MIM# [600584](#)), *GATA4* (MIM# [600576](#)) and *TBX5* (MIM# [601620](#)) and these mutations are often observed in patients with atrial, ventricular and atrioventricular septation defects. Although these family studies have been useful in uncovering genes linked to CHD, population-based studies show so far, rare detection of mutations in unrelated patients with CHD (e.g. Rajagopal et al., 2007;Posch et al., 2008); therefore, pointing to a multifactorial cause of disease. Furthermore, mutations exhibit variable expression, in which different cardiac malformations occur even from the same mutation, suggesting modifying factors and epigenetic effects contributing to disease

1  
2  
3 manifestation. Indeed, a recent study which examined the effect of genetic background  
4  
5 variation on the incidence of specific heart defects in heterozygous knock-out *Nkx2-5*<sup>+/-</sup> mice  
6  
7 and in crosses to two different strains revealed that such genetic modifiers to play an  
8  
9 important role in buffering cardiac developmental pathways against a major perturbation,  
10  
11 while directing the manifestation of disease in a few (Winston et al., 2010).  
12  
13  
14

15 In this paper, we will review efforts in identifying disease-associated mutations in the  
16  
17 transcription factor gene *NKX2-5*, and the clinical significance of such mutations in the  
18  
19 pathogenesis of CHD. We summarize published germline *NKX2-5* mutations and  
20  
21 corresponding CHD phenotypes, their detection frequency, geographical location, as well as  
22  
23 functional consequence as determined by assays or bioinformatic prediction. Finally, we  
24  
25 explore different avenues in CHD pathogenesis, some of which challenge the well-accepted  
26  
27 view of a single mutation as a direct cause of disease.  
28  
29  
30  
31  
32  
33

### 34 ***NKX2-5* and its Role in Cardiac Development and Disease**

35  
36  
37 *Nkx2-5* belongs to the NK-2 family of homeodomain-containing transcription factors,  
38  
39 which are conserved in many organisms from flies to humans (Bartlett et al., 2010). Through  
40  
41 the 60-amino-acid homeodomain (HD), *Nkx2-5* interacts with DNA through a helix-turn-  
42  
43 helix DNA-binding motif of three alpha helices, with helix 3 providing binding specificity.  
44  
45 Important for *Nkx2-5* function are also other conserved regions namely, the transactivation  
46  
47 (TN) domain, and the NK2-specific domain (NK2-SD). *Nkx2-5* is a transcriptional regulator  
48  
49 during early embryonic heart development, and its absence in mice models results in  
50  
51 embryonic lethality and arrested heart development at the looping stage (see reviews, Harvey  
52  
53 et al., 2002; Akazawa and Komuro, 2005; Bartlett et al., 2010). *Nkx2-5* is also essential for the  
54  
55 formation, maturation and maintenance of the conduction system (Pashmforoush et al.,  
56  
57 2004; Jay et al., 2004). *Nkx2-5* regulates the number of cells in the cardiac conduction system  
58  
59 in a dose-dependent manner (Jay et al., 2004). While null *Nkx2-5* mice mutants appear to lack  
60

1  
2  
3 the primordium of the atrioventricular node, heterozygotes have half the number of cells.  
4  
5 Anatomic hypoplasia of the conduction system may explain some of the defects in Nkx2-5  
6  
7  
8 loss-of-function mutants. Notably, Nkx2-5 is expressed in both the first heart field (FHF) and  
9  
10 the second heart field (SHF), the two distinct sources of cardiac progenitor cells contributing  
11  
12 to different parts of the heart (Buckingham et al., 2005). This expression in progenitor cells  
13  
14 indicates a higher role for Nkx2-5 in the hierarchy of transcriptional regulators of heart  
15  
16 development.  
17  
18

19  
20 Recent studies show further roles for Nkx2-5 in heart development and perinatal  
21  
22 hearts. In mice, Nkx2-5 repression of Bmp2/Smad1 signaling regulates SHF proliferation and  
23  
24 outflow tract (OFT) morphology (Prall et al., 2007). In the cardiac fields of Nkx2-5 mutants,  
25  
26 genes controlling cardiac specification and maintenance of the progenitor state were  
27  
28 upregulated, leading initially to progenitor overspecification, but subsequently to failed SHF  
29  
30 proliferation and outflow tract (OFT) truncation. Nkx2-5-null embryos exhibited decrease in  
31  
32 SHF proliferation, resulting in a smaller outflow tract and right ventricle. In vivo Cre-lox P-  
33  
34 based lineage tracing in mice showed that Nkx2-5-expressing cardiac progenitors contributed  
35  
36 to the proepicardium (Zhou et al., 2008). Indeed, Nkx2-5 knockout resulted in abnormal  
37  
38 proepicardial development, and decreased expression of the transcription factor Wilm's  
39  
40 Tumor 1 (Wt1), which in the heart its expression is confined to the proepicardium and  
41  
42 epicardium. Furthermore, inhibiting the function of Nkx2-5 homologs (nkx2.5 and nkx2.7) in  
43  
44 zebrafish showed their involvement in the regulation of heart tube extension as well as  
45  
46 ventricular and atrial cell number (Targoff et al., 2008). The nkx-deficient heart tube failed to  
47  
48 elongate normally: its ventricular portion was atypically short and wide, and its atrial portion  
49  
50 was disorganized and sprawling. This atrial phenotype was associated with a surplus of atrial  
51  
52 cardiomyocytes; ventricular cell number decreased in nkx-deficient embryos later in  
53  
54 development, when cardiac chambers are emerging.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lastly, it has also been demonstrated using tamoxifen-inducible *Nkx2-5* knockout mice that *Nkx2-5* function is critical not only during cardiac development, but also in perinatal hearts, by regulating expression of several important gene products involved in conduction and contraction (Briggs et al., 2008). The perinatal loss of *Nkx2-5* resulted in rapid conduction and contraction defects within 4 days after the deletion of *Nkx2-5* alleles. Furthermore, using tamoxifen-inducible Cre transgene (Cre-ER), floxed-*Nkx2-5* alleles were deleted beginning at 2 weeks of age (Takeda et al., 2009). The loss of *Nkx2-5* beginning at 2 weeks of age also resulted in conduction and contraction defects, but disease progression was slower than in perinatal loss of *Nkx2-5*.

### **An Update of *NKX2-5* Germline Mutations**

The human *NKX2-5* gene maps to chromosome 5q34 and consists of two exons that encode a 324-amino-acid protein. Since the first report implicating *NKX2-5* mutations in human CHD (Schott et al., 1998), the coding region of *NKX2-5* has been consistently searched for additional disease-associated sequence alterations. There are at least 28 studies where germline *NKX2-5* mutations have been analyzed or identified in CHD (Supp. Table S1). *NKX2-5* mutations were identified in different countries, but majority were found in studies conducted in the United States and affect different regions of the gene (Supp. Figure S1, Supp. Table S2). Some mutations may appear though to cluster geographically, such as the three deletions from Japan, and the two substitutions from Germany (Supp. Figure S1).

At least 41 different *NKX2-5* germline mutations, most of which lead to amino acid change (nonsynonymous mutations) have been reported (Figure 1, Supp. Table S2). Of these 41 mutations, 33 are single nucleotide substitutions, 6 deletions and 2 insertions. The *NKX2-5* mutations are spread along the gene, and except for one at a splice site, all are located in the coding region. Mutations affect conserved regions, where 2 are in the TN domain, 14 in the homeodomain (HD), and 2 are in the NK2-SD domain. Only 5 of 41 (12%) have been

1  
2  
3 reported more than once in unrelated individuals, with c.73C>T (p.R25C) being frequently  
4  
5 detected. However, p.R25C was also found in unaffected relatives and controls; hence, its  
6  
7 pathogenicity remains unclear (Goldmuntz et al., 2001; Akcaboy et al., 2008; Esposito et al.,  
8  
9 2009; Gioli-Pereira et al., 2010).

10  
11  
12 Furthermore, *NKX2-5* mutations have been identified in both familial and sporadic  
13  
14 cases of CHD, in which 25 of 41 are familial, 14 are sporadic, and 2 are sporadic/familial  
15  
16 cases (Figure 1, Supp. Table S2). Patients are heterozygous for the *NKX2-5* mutations, and  
17  
18 frequent CHD malformations in patients with *NKX2-5* mutations are atrial septal defect  
19  
20 (ASD) with or without atrioventricular block (AV) block. Specifically, 29 of 41 mutations  
21  
22 were identified in patients with ASD II, 26 in AV block, and 25 in combined ASD II and AV  
23  
24 block. Other CHD phenotypes were also found including Tetralogy of Fallot (TOF) in 7  
25  
26 mutations, as well as ventricular septal defect (VSD) in 9 mutations. A quick characterization  
27  
28 of the 41 *NKX2-5* mutations identified in patients with CHD is depicted in Figure 2.  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Functional Significance of *NKX2-5* Mutations**

38  
39  
40 Of the 40 mutations identified in the coding region of *NKX2-5*, 25 are missense, 7  
41  
42 nonsense, 7 frameshift and 1 leading to an amino acid deletion. Most of these would affect  
43  
44 protein function as predicted by bioinformatic methods or by functional assays (Table 1). So  
45  
46 far, only 4 mutations have been predicted to have no deleterious effects on protein function.  
47  
48 Specifically, 17 mutations would lead to a truncated protein in which 11 affect both the  
49  
50 homeodomain and NK2-SD. Notably, certain mutations that are not outright nonsense in the  
51  
52 homeodomain would result in the breakage of the secondary structure (Figure 3) and /or affect  
53  
54 highly conserved residues (Figure 4). Moreover, 16 mutations exhibited impaired function in  
55  
56 all or any of the assays particularly DNA binding, transactivation activity, protein-protein  
57  
58 interaction and nuclear localization (Table 1, Supp. Table S3). Essentially, *NKX2-5* mutations  
59  
60

1  
2  
3 affecting the homeodomain resulted in reduced or loss of DNA binding, transactivation  
4 activities, and protein-protein interactions particularly with GATA4 and TBX5 (Kasahara et  
5 al., 2000;Kasahara and Benson, 2004;Zhu et al., 2000;Monzen et al., 2002;Inga et al.,  
6 2005;Esposito et al., 2009).

## 16 **Lack of Genotype-Phenotype Correlation**

17  
18 Despite *NKX2-5* hypermutability and the pathogenic potentials of *NKX2-5* germline  
19 mutations, there is lack of genotype-phenotype correlation of *NKX2-5* mutations in CHD (see  
20 also review, Benson, 2010). Notably, the detection frequency of *NKX2-5* mutations in  
21 sporadic cases of CHD is about 2% and in several studies none was found (Table 2). Most of  
22 the identified *NKX2-5* mutations are unique and diverse cardiac malformations have been  
23 associated with *NKX2-5* mutations (Figure 1). Furthermore, same CHD phenotypes have been  
24 exhibited by patients with different *NKX2-5* mutations or same *NKX2-5* mutation gave  
25 different CHD phenotypes in regards to severity even within families (see for instance, Figure  
26 1 and Supp. Table S2). Indeed, more than half of identified *NKX2-5* mutations are familial  
27 cases, and families have their private mutations.

28  
29 Even as new studies on *NKX2-5* mutations keep coming in, the picture remains  
30 basically unchanged. After genetic analysis of *NKX2-5* mutations in 230 patients with TOF, a  
31 detection frequency of 0.9% was obtained (Rauch et al., 2010). Two patients with non-  
32 syndromic TOF harbored an unknown variant each (i.e. p.C270Y and p.V315L), both located  
33 at the carboxy terminal and which did not show an effect on the transcriptional reporter assay  
34 used. The most frequent variant p.R25C was also detected in two patients. In another study,  
35 no *NKX2-5* mutations were found in 96 patients with idiopathic atrial fibrillation, a condition  
36 of arrhythmia but no visible structural defects (Boldt et al., 2009). After sequencing *NKX2-5*  
37 in 34 patients with stroke and patent foramen ovale (PFO), no pathogenic mutations were  
38 obtained (Belvis et al., 2009). All the while, *NKX2-5* mutations are not exclusive to CHD.

1  
2  
3 Indeed, *NKX2-5* mutations (p.A119S, p.R25C, p.R161P) were found in thyroid dysgenesis, in  
4 patients with or without cardiac anomalies (Dentice et al., 2006), suggesting a broader role for  
5  
6  
7  
8 *NKX2-5* in organogenesis and pathophysiology.  
9

10  
11 There are several factors that may contribute to this lack of genotype-phenotype  
12 correlation. For one, genetic background can modify the phenotypic expression of single gene  
13 mutations in mice and humans (Rajagopal et al., 2007). Indeed, modifier genes have been  
14  
15 shown to affect *NKX2-5* mutations in the pathogenesis of CHD (Kaiser et al., 2005; Winston et  
16  
17 al., 2010). There is also the possible influence of synonymous (silent) mutations and dbSNPs  
18  
19 affecting protein expression and function (Sauna et al., 2007). Such silent variants and  
20  
21 dbSNPs eventually serve as risk factors for CHD. Furthermore, buffering that can result from  
22  
23 compensation by a normally functioning second allele or a duplicated gene or a pathway that  
24  
25 maintains residual function may also explain reduced penetrance of mutations in sporadic  
26  
27 cases of CHD (see review, Bentham and Bhattacharya, 2008). These authors proposed that the  
28  
29 genetic architecture of sporadic CHD likely includes accumulation of rare nonsynonymous  
30  
31 variants in cardiac developmental genes leading to mutational loading of cardiac  
32  
33 developmental networks, copy number variation in cardiac developmental genes, and  
34  
35 common variants that may not be obviously linked to cardiac development but may alter  
36  
37 genetic buffering pathways. Moreover, as one review commented (Weismann and Gelb,  
38  
39 2007), germline mutations may not be compatible with survival of the developing embryo  
40  
41 because many of the genes that control cardiac development also play critical roles in the  
42  
43 development of other organ systems and in any case, would not likely cause CHD only.  
44  
45 Summing up, a single germline *NKX2-5* mutation as the direct cause of disease or a simple  
46  
47 Mendelian inheritance alone may not sufficiently explain disease pathogenesis. Needless to  
48  
49 say, none of the patients studied so far are homozygous for *NKX2-5* variant alleles.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Molecular Basis of CHD Pathogenesis

The landscape for CHD pathogenesis is complex. First of all, majority of CHD cases are sporadic in which patients have no family history of the disease. Indeed, the contribution of family history of any CHD among first-degree relatives to the overall prevalence of CHD is small, approximately 2-4% (Oyen et al., 2009). There is clinical or phenotype heterogeneity within affected individuals, as well as within and between families. Disease association is difficult owing to lack of clear genotype-phenotype correlation of mutations. For instance, patients harboring the same *NKX2-5* mutation have different malformations; or mutations in different genes give the same disease phenotype. Specifically, common cardiac malformations associated with *NKX2-5* mutations are AV block, ASD, and VSD. But the same structural anomalies are also observed in mutations in other transcription factor genes (see reviews, Clark et al., 2006; Nemer, 2008). ASD is associated with mutations involving *GATA4*, *TBX5* and *ZIC3*; AV block in *NKX2-5* and *TBX5*; or VSD in *GATA4* and *TBX5*. Thus, CHD is considered as a multifactorial disease, likely resulting from gene-environment interactions which eventually determine disease penetrance and expressivity. Among the environmental risk factors for CHD are chemicals, drugs, infections, and maternal diseases (reviewed in Jenkins et al., 2007).

At the molecular and cellular levels, heart development can practically go wrong in many directions leading to diverse cardiac malformations observed in CHD. Notably, heart development requires spatial and timely interactions of different transcription factors to regulate downstream targets, and breakdown of transcriptional interactions can lead to various CHD phenotypes (see reviews, Nemer, 2008; Bruneau, 2008). For example, *Nkx2-5* through the homeodomain interacts physically and synergistically with *Gata4* and *Tbx5*, such that abrogation of their interaction leads to CHD. Indeed, *NKX2-5* mutations identified in patients affecting the homeodomain have been demonstrated to result in reduced interaction with *Gata4* and *Tbx5* (Kasahara and Benson, 2004). Recently, it has been shown that *Nkx2-5* can

1  
2  
3 directly interact with Mef2c, and the physical, functional, and genetic interactions between  
4  
5 Nkx2-5 and Mef2c are necessary for ventricle formation (Vincentz et al., 2008). While  
6  
7 individual mutants for both Nkx2-5 and Mef2c had identifiable ventricles, double mutants  
8  
9 displayed ventricular hypoplasia, a more severe cardiac phenotype. Besides transcription  
10  
11 factors, Nkx2-5 can also interact with a histone methyltransferase to regulate target genes. A  
12  
13 recent study linked Nkx2-5 to Wolf-Hirschhorn syndrome (MIM #194190) where cardiac  
14  
15 septal defects are among the anomalies, through an association with Whsc1, an H3K36me3-  
16  
17 specific histone methyltransferase in mouse embryonic hearts (Nimura et al., 2009). The  
18  
19 effects of *Whsc1* haploinsufficiency increased in heterozygous *Nkx2-5* mutant hearts, and  
20  
21 reporter assays showed that *Whsc1* negatively modulated the transcriptional activity of Nkx2-  
22  
23  
24  
25  
26  
27 5.

28  
29 A complex network of signaling molecules and their signal transduction pathways  
30  
31 participates in the precise orchestration of the many morphogenetic events in heart  
32  
33 development especially in the specification, proliferation and differentiation of cardiac  
34  
35 progenitor cells (reviewed in Wagner and Siddiqui, 2007a; Wagner and Siddiqui,  
36  
37 2007b; Niessen and Karsan, 2008; Nemir and Pedrazzini, 2008; Rochais et al., 2009). Shown to  
38  
39 regulate cardiogenesis include bone morphogenetic proteins (BMP), fibroblast growth factors  
40  
41 (FGF), Wnt, Hedgehog, Nodal, retinoic acid, neuregulin, vascular endothelial growth factor  
42  
43 (VEGF) and Notch signaling pathways. Errors in these signaling pathways can impair heart  
44  
45 development. For instance, mutations in the Notch signaling pathway (McBride et al., 2008)  
46  
47 or in the Nodal signaling pathway (Roessler, 2008) have been identified in patients with  
48  
49 various cardiac anomalies.  
50  
51  
52  
53

54  
55 Furthermore, there are now studies showing that defects in chromatin remodeling can  
56  
57 lead to CHD. Chromatin remodeling allows transcriptional machinery access to gene  
58  
59 regulatory elements and is essential in heart development. Silencing of *Smarca3*, which  
60  
encodes Baf60c, a subunit of the Brg1-associated-factor (BAF) chromatin remodeling

1  
2  
3 complex, caused in ES-cell-derived mouse embryos severe cardiac malformations including  
4 hypoplastic atrium, hypoplastic right ventricle, single ventricle, abnormal outflow tract and  
5 severely impaired trabecular formation (Lickert et al., 2004). Furthermore, Baf180, a specific  
6 subunit of the PBAF form of the BAF complex is required for cardiac and placental  
7 development (Wang et al., 2004). Ablation of Baf180 in mouse embryos resulted in severe  
8 hypoplastic ventricle, ventricular septal defect and trophoblast placental defects. Recently, it  
9 has been shown that myocardial trabeculation requires Brg1, a chromatin remodeling protein,  
10 (Stankunas et al., 2008a). Trabeculation defects occurred in the absence of endocardial Brg1  
11 which resulted from the derepression of a secreted matrix metalloproteinase, ADAMTS1,  
12 which normally only increases in expression later in development to prevent excessive  
13 trabeculation.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Thus, there is justification for proposing the concept of one heart disease-several  
30 mechanisms-several genes to explain the heterogeneity of certain cardiac malformations,  
31 which is not by chance but by the heterogeneity of mechanisms (Bajolle et al., 2009).  
32 According to this concept, a certain malformation may originate from different embryology  
33 mechanisms, which in turn controlled by multiple genes. Given as example is common  
34 arterial trunk (CAT), which may result from a participation defect of progenitors from the  
35 second cardiac field and/or a migration defect of the neural crest cells and/or a rotation defect  
36 of the myocardium and/or a formation abnormality of the endocardial cushions. Further  
37 example is atrioventricular valve formation which is regulated by different genetic pathways  
38 (Joziasse et al., 2008). Disturbances in each subset of a particular pathway, i.e. ligand  
39 receptor, transcription factor or extracellular matrix proteins can all result in similar cardiac  
40 defects.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 Recently, a study showed that interactions between alleles of three *Pbx* genes, which  
58 encode homeodomain transcription factors, are sufficient to determine the phenotypic  
59 presentation of CHD in mice (Stankunas et al., 2008b). A major role is served by *Pbx1*, whose  
60

1  
2  
3 inactivation results in persistent truncus arteriosus (PTA). Reduction or absence of *Pbx2* or  
4  
5 *Pbx3* leads to *Pbx1* haploinsufficiency and specific malformations that resemble Tetralogy of  
6  
7 Fallot, overriding aorta with ventricular septal defect, and bicuspid aortic valves. Disruption  
8  
9 of *Meis1*, which encodes a *Pbx* DNA-binding partner, results in cardiac anomalies that  
10  
11 resemble those caused by *Pbx* mutations. Altogether, these findings among others challenge  
12  
13 the well-accepted paradigm in autosomal dominant monogenic disease that 1 mutation in a  
14  
15 single gene as the direct cause of disease, and have major implication in clinical evaluation,  
16  
17 diagnosis, and management of families with a genetic cardiovascular disease (see for instance,  
18  
19 Kelly and Semsarian, 2009).  
20  
21  
22  
23  
24  
25  
26

## 27 **Learning from the Leipzig Collection of Malformed Hearts**

28  
29  
30 Model organisms especially mice provide insights into the molecular mechanisms  
31  
32 leading to CHD. But results can be species-specific and only a minority of mutations in these  
33  
34 genes have been related to CHD in humans (see Bruneau, 2008). Furthermore, genetic studies  
35  
36 on CHD are usually based on blood samples and such analysis may not reveal complete  
37  
38 genetic alterations leading to the disease. To gain insights into the molecular causes of CHD,  
39  
40 we conducted in the past genetic analysis of *NKX2-5* and other cardiac-specific transcription  
41  
42 factor genes, most recently on *HAND1* (MIM# [602406](#)), in a rare collection of  
43  
44 morphologically, well-characterized explanted, malformed hearts stored in formalin for many  
45  
46 years (Reamon Buettner and Borlak, 2004; Reamon-Buettner et al., 2004; 2008; 2009). This  
47  
48 research identified somatic mutations of cardiac-specific transcription factor genes as a  
49  
50 possible disease-causing mechanism as discussed below.  
51  
52  
53  
54  
55

56 Direct sequencing of different cardiac-specific transcription factor genes in 'affected'  
57  
58 tissues of malformed hearts revealed frequent disease-associated mutations which were  
59  
60 mainly absent in 'unaffected' tissues in the same patient's heart. This finding indicates somatic  
mosaicism and somatic origin of mutations. Many patients displayed multiple deleterious

1  
2  
3 mutations not only in one but several transcription factor genes. While for some investigators  
4  
5 in the field, it would be easiest to explain the findings from the Leipzig heart collection as  
6  
7 artifacts on the basis of degraded DNA owing to many years of storage in formalin solution  
8  
9 (Draus et al., 2009), the study on such a rare collection of malformed hearts may lead to  
10  
11 important insights on heart development and CHD. Here are some of the pros and cons of the  
12  
13 scientific discussion.  
14  
15

### 16 17 **1. Somatic mutations as a molecular rationale for CHD**

18  
19 Somatic mutations may result from environmental insults and epigenetic instability to  
20  
21 provide a molecular rationale for CHD. Although somatic mutations are well known in  
22  
23 cancer, they can also occur in non-cancer diseases. For example, somatic mutations in the  
24  
25 gene *TEK* encoding the endothelial cell tyrosine kinase receptor TIE2 were identified in  
26  
27 lesions from patients with sporadic venous malformations (Limaye et al., 2009). The somatic  
28  
29 mutations included a frequent p.L914F substitution and several double mutations in *cis*, all of  
30  
31 which resulted in ligand-independent TIE2 hyperphosphorylation in vitro. Somatic mutations  
32  
33 were also identified in *GJA5* gene encoding cardiac gap-junction protein connexin 40 in  
34  
35 cardiac tissues of patients with atrial fibrillation (Gollob et al., 2006). Atrial fibrillation is the  
36  
37 most common type of cardiac arrhythmia and a leading cause of cardiovascular morbidity,  
38  
39 particularly stroke.  
40  
41  
42  
43  
44

### 45 46 **2. Multiple mutations in complex cardiac malformations**

47  
48 The presence of multiple mutations in patients with complex heart malformations may  
49  
50 be a reflection of disease severity. Indeed, there are now studies to show that the presence of  
51  
52 multiple disease-causing mutations in the same gene or in different genes can be an indication  
53  
54 of disease severity (Kelly and Semsarian, 2009). In familial hypertrophic cardiomyopathy  
55  
56 (FHC) which is characterized by genetic and clinical heterogeneity, patients with two FHC-  
57  
58 causing mutations typically had more severe phenotype (i.e. earlier onset of disease, greater  
59  
60 left ventricular hypertrophy and a higher incidence of sudden cardiac death events) compared

1  
2  
3 with carriers of single mutation (Tsoutsman et al., 2008a;Tsoutsman et al., 2008b).

4  
5 Furthermore, in familial transposition of great arteries (TGA) some patients harbored more  
6  
7 than one mutation in laterality genes which presumably influenced cardiac phenotype (De  
8  
9 Luca et al., 2010).

### 10 11 12 **3. A structural malformation may result from combined effects of deleterious mutations in** 13 14 **several transcription factor genes**

15  
16  
17 Certain malformations may have resulted from combined effects of deleterious  
18  
19 mutations in several transcription factor genes. In the hypoplastic hearts group, a frameshift  
20  
21 mutation p.A126fs (HAND1) was frequently detected in hypoplastic ventricles (Reamon-  
22  
23 Buettner et. al., 2008). But further analysis led to the detection of additional loss-of-function  
24  
25 mutations affecting the 2nd zinc finger of GATA4 and homeodomain of NKX2-5  
26  
27 (unpublished results). For example, in the hypoplastic left ventricle of patient A82, we  
28  
29 detected in HAND1 p.A126fs; in GATA4 p.R266X; and in NKX2-5 homozygous for  
30  
31 p.L116P, p.T178M, p.K192T.  
32  
33  
34  
35

### 36 37 **4. Indications of transient hypermutability/ genetic instability in cardiac tissues of CHD** 38 39 **patients**

40  
41 Hypermutability varied among the different transcription factor genes, but mutations  
42  
43 were non-random and closely-spaced. The multiple mutations observed in the affected tissues  
44  
45 were possibly the result of various haplotypes. Specifically, depending on the stretch of DNA  
46  
47 being analyzed, the closely-spaced sequence alterations could involve those in the coding or  
48  
49 non-coding regions, and when in the coding region, mutations could be synonymous or non-  
50  
51 synonymous. For example, in two patients affected by VSD, we found 11 non-random,  
52  
53 closely-spaced mutations in *NKX2-5* within 362-bp spanning intronic and coding sequences of  
54  
55 exon 2. In this window, the separation of an *NKX2-5* mutation to the next ranged from 3 bp to  
56  
57 121 bp, but majority was less than 30 bp. Moreover, after cloning of a PCR fragment  
58  
59 'heterozygous' for the multiple mutations in an analyzed transcription factor gene, more than  
60

1  
2  
3 the two expected haplotypes or alleles were found. In some cases, all the variants occurred in  
4  
5 *cis*. The occurrence of closely-spaced multiple mutations in human genes has been suggested  
6  
7 to be possible signatures of transient hypermutability, a mutational mechanism with the  
8  
9 potential to generate multiple synchronous mutations, resulting from a perturbation of one of  
10  
11 the many transactions that maintain genetic stability (Chen et al., 2009). Specifically, transient  
12  
13 hypermutability may result from (1) the deregulated expression of, or conformational change  
14  
15 in, either a replicative DNA polymerase or another protein involved in the maintenance of  
16  
17 replication fidelity; (2) the disruption of the balance of the nucleotide pool; or (3) the  
18  
19 recruitment of error-prone DNA polymerases in DNA replication or repair (reviewed in Chen  
20  
21 et al., 2009).  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Future Directions**

31  
32 Understanding the molecular process leading to CHD should provide important  
33  
34 insights into the etiology and treatment of patients. This is a difficult task as CHD is complex  
35  
36 entailing defects in multiple genes and different pathways. A good grasp of CHD would thus  
37  
38 require a whole-genome functional approach, in which for a specific structural defect a  
39  
40 combination of different genes and associated pathways involving transcriptional machinery,  
41  
42 signal transduction, and chromatin remodeling will be simultaneously interrogated. But with  
43  
44 high-throughput technologies in different 'omics' available, as well as accumulating evidence  
45  
46 from animal models, this may be no longer a monumental undertaking. Eventually, there is  
47  
48 the task ahead to translate discoveries to human CHD, although in future genetic studies  
49  
50 corresponding molecular events may have been identified by then to explain genetic  
51  
52 heterogeneity, reduced penetrance and variable expressivity owing to complex inheritance of  
53  
54 the disease. Nevertheless, there is also a need to better understand environmental factors that  
55  
56 possibly cause CHD, such as intrauterine stress shortly after conception owing to  
57  
58 environmental contaminants. Indeed, there is evidence that in utero DNA damage from  
59  
60

1  
2  
3 environmental pollution is associated with somatic gene mutation in newborns (Perera et al.,  
4  
5 2002), and that there are indications for increased risk of CHD in polluted areas (Brook et al.,  
6  
7 2004). Additional research areas should be addressed:  
8  
9

10  
11  
12 1. To gain deeper knowledge of how epigenetic regulation influence molecular mechanisms  
13  
14 of heart development and its disruptions in CHD. Epigenetics describes heritable changes in  
15  
16 gene expression that are not coded in the DNA sequence, but an interplay of DNA  
17  
18 methylation, histone modifications and expression of non-coding RNAs, in the regulation of  
19  
20 gene expression patterns. Epigenetic mechanisms are essential for development and  
21  
22 differentiation, but they can become misdirected leading to birth malformations and various  
23  
24 human diseases. Indeed, efforts are now underway in this direction, where for instance,  
25  
26 deletion of miRNAs in mice during cardiogenesis has been shown to result in double-outlet  
27  
28 right ventricle with a concurrent ventricular septal defect (Saxena and Tabin, 2010).  
29  
30  
31  
32  
33  
34  
35  
36 2. To decipher mechanisms of chromatin remodeling and DNA repair in heart development  
37  
38 and CHD. Essentially, DNA is packaged, through histone and non-histone proteins, into a  
39  
40 condensed structure termed chromatin. The nucleosome is the basic repeating unit of  
41  
42 chromatin, consisting of about 147-bp of DNA wrapped approximately two times around a  
43  
44 histone core comprising two copies of each of the histone proteins H2A, H2B, H3 and H4.  
45  
46 Through chromatin remodeling, histone-DNA is disrupted resulting in a 'relaxed' chromatin,  
47  
48 which then allows transcriptional machinery contact DNA to turn genes 'on' or 'off'. But more  
49  
50 important, chromatin remodeling also facilitates DNA-damage-response proteins access DNA  
51  
52 lesions and eventually initiate repair to maintain genome integrity (for reviews, Osley and  
53  
54 Shen, 2006;Osley et al., 2007). Chromatin remodeling factors may involve those modifying  
55  
56 enzymes that catalyze post-translational modifications of residues on both histone core and  
57  
58 tails; or those enzymes that use ATP hydrolysis to disrupt histone-DNA leading to structurally  
59  
60

1  
2  
3 altered nucleosomes, or to sliding or eviction of nucleosomes. Although there are now studies  
4 showing an essential role of chromatin remodeling with respect to transcriptional regulation in  
5 heart development and CHD (Lickert et al., 2004;Wang et al., 2004), none has been found so  
6 far on DNA repair. The role of DNA repair would be of utmost importance during early heart  
7 development, notably in embryonic cells and committed precursors of the mesoderm.  
8  
9

10  
11  
12  
13  
14  
15  
16  
17 3. To identify molecular causes of hypermutability of genes and subsequent contribution to  
18 CHD, and explore whether activation-induced cytidine deaminase (AID) causes somatic  
19 hypermutability of cardiogenic genes in CHD. AID is a master regulator of diversification of  
20 antibody genes by initiating the processes of somatic hypermutation (SHM), gene conversion  
21 (IGC), and class-switch recombination (CSR) in B-lymphocytes (see reviews, Teng and  
22 Papavasiliou, 2007;Liu and Schatz, 2009). Essentially, AID induces somatic hypermutability  
23 of immunoglobulin (*Ig*) genes by cytosine deamination resulting in the generation of a uracil  
24 and thus converting a C:G basepair into a U:G mismatch, which is then processed into a  
25 mutation by different mechanisms. For instance, DNA replication over the uracil leads to C to  
26 T or G to A transition mutations. Alternatively, removal of the uracil by uracil-DNA  
27 glycosylase (UNG) generates an abasic site in the DNA, which when replicated across yields  
28 transition and transversion mutations at the C:G basepair. The U:G mismatch can also be  
29 recognized by the mismatched repair factors allowing the generation of either mutations at  
30 A:T basepairs by error prone patch repair or a nicked DNA recombination substrate.  
31  
32 However, there are now evidences for AID to deaminate not only *Ig* genes, but many more  
33 genes including numerous oncogenes implicated in B-cell tumorigenesis (Liu and Schatz,  
34 2009). Indeed, AID can be potentially functional in a variety mammalian of non-B cells  
35 triggering genome-wide hypermutation and consequently to genetic instability and neoplasm  
36 (Perez-Duran et al., 2007).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ACKNOWLEDGEMENTS

We thank the Institute of Anatomy, University of Leipzig for providing the heart collection; to Dr. Mike Resnick and Dr. Alberto Inga for the fruitful discussions; and A. Roskowitz and A. Hiemisch, for the excellent technical support. The financial support of the Lower Saxony Ministry of Science and Culture, Germany to JB is greatly appreciated.

For Peer Review

## References

- 1  
2  
3  
4  
5  
6 Akazawa H, Komuro I. 2005. Cardiac transcription factor Csx/Nkx2-5: Its role in cardiac  
7  
8 development and diseases. *Pharmacol Ther* 107: 252-268.  
9  
10 Akcaboy MI, Cengiz FB, Inceoglu B, Ucar T, Atalay S, Tutar E, Tekin M. 2008. The effect of  
11  
12 p.Arg25Cys alteration in NKX2-5 on conotruncal heart anomalies: mutation or  
13  
14 polymorphism? *Pediatr Cardiol* 29: 126-129.  
15  
16  
17 Bajolle F, Zaffran S, Bonnet D. 2009. Genetics and embryological mechanisms of congenital  
18  
19 heart disease. *Arch Cardiovasc Dis* 102: 59-63.  
20  
21  
22 Bartlett H, Veenstra GJ, Weeks DL. 2010. Examining the cardiac NK-2 genes in early heart  
23  
24 development. *Pediatr Cardiol* 31:335-341.  
25  
26  
27 Belvis R, Tizzano EF, Marti-Fabregas J, Leta RG, Baena M, Carreras F, Pons-Llado G,  
28  
29 Baiget M, and Marti-Vilalta JL. 2009. Mutations in the NKX2-5 gene in patients with  
30  
31 stroke and patent foramen ovale. *Clin Neurol Neurosurg* 111: 574-578.  
32  
33  
34 Benson DW. 2010. Genetic origins of pediatric heart disease. *Pediatr Cardiol* 31: 422-429.  
35  
36  
37 Benson DW, Silberbach GM, Kavanaugh-McHugh A, Cottrill C, Zhang Y, Riggs S, Smalls  
38  
39 O, Johnson MC, Watson MS, Seidman JG, Seidman CE, Plowden J, Kugler JD. 1999.  
40  
41 Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental  
42  
43 pathways. *J Clin Invest* 104: 1567-1573.  
44  
45  
46 Bentham J, Bhattacharya S. 2008. Genetic mechanisms controlling cardiovascular  
47  
48 development. *Ann N Y Acad Sci* 1123: 10-19.  
49  
50  
51 Bjornstad PG, Leren TP. 2009. Familial atrial septal defect in the oval fossa with progressive  
52  
53 prolongation of the atrioventricular conduction caused by mutations in the NKX2.5 gene.  
54  
55 *Cardiol Young* 19: 40-44.  
56  
57  
58 Boldt LH, Posch MG, Perrot A, Polotzki M, Rolf S, Parwani AS, Huemer M, Wutzler A,  
59  
60 Ozcelik C, Haverkamp W. 2009. Mutational analysis of the PITX2 and NKX2-5 genes in  
patients with idiopathic atrial fibrillation. *Int J Cardiol*. Epub ahead of print

1  
2  
3 (doi:10.1016/j.ijcard.2009.11.023).  
4

5  
6 Briggs LE, Takeda M, Cuadra AE, Wakimoto H, Marks MH, Walker AJ, Seki T, Oh SP, Lu  
7  
8 JT, Sumners C, Raizada MK, Horikoshi N, Weinberg EO, Yasui K, Ikeda Y, Chien KR,  
9  
10 Kasahara H. 2008. Perinatal loss of Nkx2-5 results in rapid conduction and contraction  
11  
12 defects. *Circ Res* 103: 580-590.  
13

14  
15 Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M,  
16  
17 Samet J, Smith SC, Jr., Tager I. 2004. Air pollution and cardiovascular disease: a statement  
18  
19 for healthcare professionals from the Expert Panel on Population and Prevention Science of  
20  
21 the American Heart Association. *Circulation* 109: 2655-2671.  
22  
23

24  
25 Bruneau BG. 2008. The developmental genetics of congenital heart disease. *Nature* 451: 943-  
26  
27 948.  
28

29  
30 Buckingham M, Meilhac S, Zaffran S. 2005. Building the mammalian heart from two sources  
31  
32 of myocardial cells. *Nat Rev Genet* 6: 826-835.  
33

34  
35 Chen JM, Ferec C, Cooper DN. 2009. Closely-spaced multiple mutations as potential  
36  
37 signatures of transient hypermutability in human genes. *Hum Mutat* 30: 1435-1448.  
38

39  
40 Clark KL, Yutzey KE, Benson DW. 2006. Transcription factors and congenital heart defects.  
41  
42 *Annu Rev Physiol* 68: 97-121.  
43

44  
45 Combs MD, Yutzey KE. 2009. Heart valve development: regulatory networks in development  
46  
47 and disease. *Circ Res* 105: 408-421.  
48

49  
50 De Luca A, Sarkozy A, Consoli F, Ferese R, Guida V, Dentici ML, Mingarelli R, Bellacchio  
51  
52 E, Tuo G, Limongelli G, Digilio MC, Marino B, Dallapiccola B. 2010. Familial  
53  
54 transposition of great arteries caused by multiple mutations in laterality genes. *Heart*  
55  
56 96:673-677.  
57

58  
59 Dentice M, Cordeddu V, Rosica A, Ferrara AM, Santarpia L, Salvatore D, Chiovato L, Perri  
60  
A, Moschini L, Fazzini C, Olivieri A, Costa P, Stoppioni V, Baserga M, De Felice M,  
Sorcini M, Fenzi G, Di Lauro R, Tartaglia M, Macchia PE. 2006. Missense mutation in the

1  
2  
3 transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid  
4  
5 dysgenesis. *J Clin Endocrinol Metab* 91: 1428-1433.

6  
7  
8 Draus JM, Jr., Hauck MA, Goetsch M, Austin EH, III, Tomita-Mitchell A, Mitchell ME.  
9  
10 2009. Investigation of somatic NKX2-5 mutations in congenital heart disease. *J Med Genet*  
11  
12 46: 115-122.

13  
14  
15 Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, Grossfeld P, Fatkin D, Jones  
16  
17 O, Hayes P, Feneley M, Harvey RP. 2003. Cardiac homeobox gene NKX2-5 mutations and  
18  
19 congenital heart disease: associations with atrial septal defect and hypoplastic left heart  
20  
21 syndrome. *J Am Coll Cardiol* 41: 2072-2076.

22  
23  
24 Esposito G, Grutter G, Drago F, Costa MW, De Santis A, Bosco G, Marino B, Bellacchio E,  
25  
26 Lepri F, Harvey RP, Sarkozy A, Dallapiccola B. 2009. Molecular analysis of PRKAG2,  
27  
28 LAMP2, and NKX2-5 genes in a cohort of 125 patients with accessory atrioventricular  
29  
30 connection. *Am J Med Genet A* 149A: 1574-1577.

31  
32  
33  
34 Gioli-Pereira L, Pereira AC, Mesquita SM, Xavier-Neto J, Lopes AA, Krieger JE. 2010.  
35  
36 NKX2.5 mutations in patients with non-syndromic congenital heart disease. *Int J Cardiol*  
37  
38 138:261-265.

39  
40  
41 Goldmuntz E, Geiger E, Benson DW. 2001. NKX2.5 mutations in patients with tetralogy of  
42  
43 fallot. *Circulation* 104: 2565-2568.

44  
45  
46 Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS,  
47  
48 Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D.  
49  
50 2006. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. *N Engl J*  
51  
52 *Med* 354: 2677-2688.

53  
54  
55 Gutierrez-Roelens I, De Roy L, Ovaert C, Sluysmans T, Devriendt K, Brunner HG, Viskula  
56  
57 M. 2006. A novel CSX/NKX2-5 mutation causes autosomal-dominant AV block: are atrial  
58  
59 fibrillation and syncopes part of the phenotype? *Eur J Hum Genet* 14: 1313-1316.  
60

- 1  
2  
3 Gutierrez-Roelens I, Sluysmans T, Gewillig M, Devriendt K, Vikkula M. 2002. Progressive  
4 AV-block and anomalous venous return among cardiac anomalies associated with two  
5  
6 novel missense mutations in the CSX/NKX2-5 Gene. *Hum Mutat* 20: 75-76.  
7  
8  
9  
10 Hamanoue H, Rahayuningsih SE, Hirahara Y, Itoh J, Yokoyama U, Mizuguchi T, Saitsu H,  
11  
12 Miyake N, Hirahara F, Matsumoto N. 2009. Genetic screening of 104 patients with  
13  
14 congenitally malformed hearts revealed a fresh mutation of GATA4 in those with atrial  
15  
16 septal defects. *Cardiol Young* 19: 482-485.  
17  
18  
19  
20 Harvey RP, Lai D, Elliott D, Biben C, Solloway M, Prall O, Stennard F, Schindeler A, Groves  
21  
22 N, Lavulo L, Hyun C, Yeoh T, Costa M, Furtado M, Kirk E. 2002. Homeodomain factor  
23  
24 Nkx2-5 in heart development and disease. *Cold Spring Harb Symp Quant Biol* 67: 107-114.  
25  
26  
27 Hirayama-Yamada K, Kamisago M, Akimoto K, Aotsuka H, Nakamura Y, Tomita H,  
28  
29 Furutani M, Imamura S, Takao A, Nakazawa M, Matsuoka R. 2005. Phenotypes with  
30  
31 GATA4 or NKX2.5 mutations in familial atrial septal defect. *Am J Med Genet A* 135: 47-  
32  
33 52.  
34  
35  
36 Hobbs CA, Cleves MA, Keith C, Ghaffar S, James SJ. 2005. NKX2.5 and congenital heart  
37  
38 defects: A population-based study. *Am J Med Genet A* 134: 223-225.  
39  
40  
41 Hosoda T, Komuro I, Shiojima I, Hiroi Y, Harada M, Murakawa Y, Hirata Y, Yazaki Y.  
42  
43 1999. Familial atrial septal defect and atrioventricular conduction disturbance associated  
44  
45 with a point mutation in the cardiac homeobox gene CSX/NKX2-5 in a Japanese patient.  
46  
47 *Jpn Circ J* 63: 425-426.  
48  
49  
50 Ikeda Y, Hiroi Y, Hosoda T, Utsunomiya T, Matsuo S, Ito T, Inoue J, Sumiyoshi T, Takano  
51  
52 H, Nagai R, Komuro I. 2002. Novel point mutation in the cardiac transcription factor  
53  
54 CSX/NKX2.5 associated with congenital heart disease. *Circ J* 66: 561-563.  
55  
56  
57 Inga A, Reamon-Buettner SM, Borlak J, Resnick MA. 2005. Functional dissection of  
58  
59 sequence-specific NKX2-5 DNA binding domain mutations associated with human heart  
60  
septation defects using a yeast-based system. *Hum Mol Genet* 14: 1965-1975.

- 1  
2  
3 Jay PY, Harris BS, Maguire CT, Buerger A, Wakimoto H, Tanaka M, Kupersmidt S, Roden  
4  
5 DM, Schultheiss TM, O'Brien TX, Gourdie RG, Berul CI, Izumo S. 2004. Nkx2-5 mutation  
6  
7 causes anatomic hypoplasia of the cardiac conduction system. *J Clin Invest* 113: 1130-  
8  
9 1137.
- 10  
11  
12 Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA,  
13  
14 Webb CL. 2007. Noninherited risk factors and congenital cardiovascular defects: current  
15  
16 knowledge: a scientific statement from the American Heart Association Council on  
17  
18 Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.  
19  
20 *Circulation* 115: 2995-3014.
- 21  
22  
23  
24  
25 Joziassse IC, van de Smagt JJ, Smith K, Bakkers J, Sieswerda GJ, Mulder BJ, Doevendans PA.  
26  
27 2008. Genes in congenital heart disease: atrioventricular valve formation. *Basic Res*  
28  
29 *Cardiol* 103: 216-227.
- 30  
31  
32 Kaiser K, Takematsu M, Jay PY. 2005. Modifier genes in the pathogenesis of congenital heart  
33  
34 disease. *Pediatr Res* 58: 818.
- 35  
36  
37 Kasahara H, Benson DW. 2004. Biochemical analyses of eight NKX2.5 homeodomain  
38  
39 missense mutations causing atrioventricular block and cardiac anomalies. *Cardiovasc Res*  
40  
41 64: 40-51.
- 42  
43  
44 Kasahara H, Lee B, Schott JJ, Benson DW, Seidman JG, Seidman CE, Izumo S. 2000. Loss  
45  
46 of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations  
47  
48 associated with congenital heart disease. *J Clin Invest* 106: 299-308.
- 49  
50  
51 Kelly M, Semsarian M. 2009. Multiple mutations in genetic cardiovascular disease: a marker  
52  
53 of disease severity? *Circ Cardiovasc Genet* 2: 182-190.
- 54  
55  
56  
57  
58  
59  
60 Khetyar M, Tinworth L, Syrris P, Abushaban L, Abdulazzaq Y, Silengo M, Carvalho J, Carter  
N. 2008. NKX2.5/NKX2.6 mutations are not a common cause of isolated type 1 truncus  
arteriosus in a small cohort of multiethnic cases. *Genet Test* 12: 467-469.

- 1  
2  
3 Konig K, Will JC, Berger F, Muller D, Benson DW. 2006. Familial congenital heart disease,  
4 progressive atrioventricular block and the cardiac homeobox transcription factor gene  
5 NKX2.5: identification of a novel mutation. *Clin Res Cardiol* 95: 499-503.  
6  
7  
8  
9  
10 Leong FT, Freeman LJ, Keavney BD. 2009. Fresh fields and pathways new: recent genetic  
11 insights into cardiac malformation. *Heart* 95: 442-447.  
12  
13  
14  
15 Lickert H, Takeuchi JK, von B, I, Walls JR, McAuliffe F, Adamson SL, Henkelman RM,  
16  
17 Wrana JL, Rossant J, Bruneau BG. 2004. Baf60c is essential for function of BAF  
18 chromatin remodelling complexes in heart development. *Nature* 432: 107-112.  
19  
20  
21  
22 Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L,  
23  
24 Boon LM, Vikkula M. 2009. Somatic mutations in angiotensin receptor gene TEK cause  
25 solitary and multiple sporadic venous malformations. *Nat Genet* 41: 118-124.  
26  
27  
28  
29 Liu M, Schatz DG. 2009. Balancing AID and DNA repair during somatic hypermutation.  
30  
31 *Trends Immunol* 30: 173-181.  
32  
33  
34 Majumdar R, Yagubyan M, Sarkar G, Bolander ME, Sundt TM, III. 2006. Bicuspid aortic  
35 valve and ascending aortic aneurysm are not associated with germline or somatic  
36 homeobox NKX2-5 gene polymorphism in 19 patients. *J Thorac Cardiovasc Surg* 131:  
37  
38 1301-1305.  
39  
40  
41  
42  
43 McBride KL, Riley MF, Zender GA, Fitzgerald-Butt SM, Towbin JA, Belmont JW, Cole SE.  
44  
45 2008. NOTCH1 mutations in individuals with left ventricular outflow tract malformations  
46 reduce ligand-induced signaling. *Hum Mol Genet* 17: 2886-2893.  
47  
48  
49  
50 McElhinney DB, Geiger E, Blinder J, Woodrow BD, Goldmuntz E. 2003. NKX2.5 mutations  
51 in patients with congenital heart disease. *J Am Coll Cardiol* 42: 1650-1655.  
52  
53  
54  
55 Monzen K, Zhu W, Kasai H, Hiroi Y, Hosoda T, Akazawa H, Zou Y, Hayashi D, Yamazaki  
56  
57 T, Nagai R, Komuro I. 2002. Dual effects of the homeobox transcription factor Csx/Nkx2-5  
58 on cardiomyocytes. *Biochem Biophys Res Commun* 298: 493-500.  
59  
60

- 1  
2  
3 Nemer M. 2008. Genetic insights into normal and abnormal heart development. *Cardiovasc*  
4  
5 *Pathol* 17: 48-54.  
6  
7  
8 Nemir M, Pedrazzini T. 2008. Functional role of Notch signaling in the developing and  
9  
10 postnatal heart. *J Mol Cell Cardiol* 45: 495-504.  
11  
12  
13 Niessen K, Karsan A. 2008. Notch signaling in cardiac development. *Circ Res* 102: 1169-  
14  
15 1181.  
16  
17  
18 Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, Kaneda Y. 2009. A histone  
19  
20 H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. *Nature* 460:  
21  
22 287-291.  
23  
24  
25 Osley MA, Shen X. 2006. Altering nucleosomes during DNA double-strand break repair in  
26  
27 yeast. *Trends Genet* 22: 671-677.  
28  
29  
30 Osley MA, Tsukuda T, Nickoloff JA. 2007. ATP-dependent chromatin remodeling factors  
31  
32 and DNA damage repair. *Mutat Res* 618: 65-80.  
33  
34  
35 Oyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. 2009. Recurrence of  
36  
37 congenital heart defects in families. *Circulation* 120: 295-301.  
38  
39  
40 Pabst S, Wollnik B, Rohmann E, Hintz Y, Glanzer K, Vetter H, Nickenig G, Grohe C. 2008.  
41  
42 A novel stop mutation truncating critical regions of the cardiac transcription factor NKX2-5  
43  
44 in a large family with autosomal-dominant inherited congenital heart disease. *Clin Res*  
45  
46 *Cardiol* 97: 39-42.  
47  
48  
49 Pashmforoush M, Lu JT, Chen H, Amand TS, Kondo R, Pradervand S, Evans SM, Clark B,  
50  
51 Feramisco JR, Giles W, Ho SY, Benson DW, Silberbach M, Shou W, Chien KR. 2004.  
52  
53 Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage  
54  
55 specification leads to progressive cardiomyopathy and complete heart block. *Cell* 117: 373-  
56  
57 386.  
58  
59  
60 Perez-Duran P, de Yébenes VG, Ramiro AR. 2007. Oncogenic events triggered by AID, the  
adverse effect of antibody diversification. *Carcinogenesis* 28: 2427-2433.

- 1  
2  
3 Perera F, Hemminki K, Jedrychowski W, Whyatt R, Campbell U, Hsu Y, Santella R,  
4  
5 Albertini R, O'Neill JP. 2002. In utero DNA damage from environmental pollution is  
6  
7 associated with somatic gene mutation in newborns. *Cancer Epidemiol Biomarkers Prev*  
8  
9 11: 1134-1137.  
10  
11  
12 Posch MG, Perrot A, Schmitt K, Mittelhaus S, Esenwein EM, Stiller B, Geier C, Dietz R,  
13  
14 Gessner R, Ozcelik C, Berger F. 2008. Mutations in GATA4, NKX2.5, CRELD1, and  
15  
16 BMP4 are infrequently found in patients with congenital cardiac septal defects. *Am J Med*  
17  
18 *Genet A* 146: 251-253.  
19  
20  
21 Prall OW, Menon MK, Solloway MJ, Watanabe Y, Zaffran S, Bajolle F, Biben C, McBride  
22  
23 JJ, Robertson BR, Chaulet H, Stennard FA, Wise N, Schaft D, Wolstein O, Furtado MB,  
24  
25 Shiratori H, Chien KR, Hamada H, Black BL, Saga Y, Robertson EJ, Buckingham ME,  
26  
27 Harvey RP. 2007. An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart  
28  
29 progenitor specification and proliferation. *Cell* 128: 947-959.  
30  
31  
32 Rajagopal SK, Ma Q, Obler D, Shen J, Manichaikul A, Tomita-Mitchell A, Boardman K,  
33  
34 Briggs C, Garg V, Srivastava D, Goldmuntz E, Broman KW, Woodrow BD, Smoot LB, Pu  
35  
36 WT. 2007. Spectrum of heart disease associated with murine and human GATA4 mutation.  
37  
38 *J Mol Cell Cardiol* 43:677-685.  
39  
40  
41 Rauch R, Hofbeck M, Zweier C, Koch A, Zink S, Hoyer J, Kaulitz R, Singer H, Rauch A.  
42  
43 2010. Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot.  
44  
45 *J Med Genet* 47:321-331  
46  
47  
48 Reamon-Buettner SM, Borlak J. 2004. Somatic NKX2-5 mutations as a novel mechanism of  
49  
50 disease in complex congenital heart disease. *J Med Genet* 41: 684-690.  
51  
52  
53 Reamon-Buettner SM, Hecker H, Spanel-Borowski K, Craatz S, Kuenzel E, Borlak J. 2004.  
54  
55 Novel NKX2-5 mutations in diseased heart tissues of patients with cardiac malformations.  
56  
57  
58 *Am J Pathol* 164: 2117-2125.  
59  
60

- 1  
2  
3 Reamon-Buettner SM, Ciribilli Y, Inga A, Borlak J. 2008. A loss-of-function mutation in the  
4 binding domain of HAND1 predicts hypoplasia of the human hearts. *Hum Mol Genet* 17:  
5 1397-1405.  
6  
7  
8  
9  
10 Reamon-Buettner SM, Ciribilli Y, Traverso I, Kuhls B, Inga A, Borlak J. 2009. A functional  
11 genetic study identifies HAND1 mutations in septation defects of the human heart. *Hum*  
12 *Mol Genet* 18: 3567-3578.  
13  
14  
15  
16  
17 Roessler E, Ouspenskaia MV, Karkera JD, Velez JI, Kantipong A, Lacbawan F, Bowers P,  
18 Belmont JW, Towbin JA, Goldmuntz E, Feldman B, Muenke M. 2008. Reduced NODAL  
19 signaling strength via mutation of several pathway members including FOXH1 is linked to  
20 human heart defects and holoprosencephaly. *Am J Hum Genet* 83: 18-29.  
21  
22  
23  
24  
25  
26  
27 Rifai L, Maazouzi W, Sefiani A. 2006. Novel point mutation in the NKX2-5 gene in a  
28 Moroccan family with atrioventricular conduction disturbance and an atrial septal defect in  
29 the oval fossa. *Cardiol Young* 17: 107-109.  
30  
31  
32  
33  
34 Rochais F, Mesbah K, Kelly RG. 2009. Signaling pathways controlling second heart field  
35 development. *Circ Res* 104: 933-942.  
36  
37  
38  
39 Sarkozy A, Conti E, Neri C, D'Agostino R, Digilio MC, Esposito G, Toscano A, Marino B,  
40 Pizzuti A, Dallapiccola B. 2005. Spectrum of atrial septal defects associated with mutations  
41 of NKX2.5 and GATA4 transcription factors. *J Med Genet* 42: e16.  
42  
43  
44  
45  
46 Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. 2007. Silent polymorphisms  
47 speak: how they affect pharmacogenomics and the treatment of cancer. *Cancer Res* 67:  
48 9609-9612.  
49  
50  
51  
52  
53 Saxena A, Tabin CJ. 2010. miRNA-processing enzyme Dicer is necessary for cardiac outflow  
54 tract alignment and chamber septation. *Proc Natl Acad Sci U S A* 107:87-91.  
55  
56  
57  
58 Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron BJ, Seidman  
59 CE, Seidman JG. 1998. Congenital heart disease caused by mutations in the transcription  
60 factor NKX2-5. *Science* 281: 108-111.

- 1  
2  
3 Stankunas K, Hang CT, Tsun ZY, Chen H, Lee NV, Wu JI, Shang C, Bayle JH, Shou W,  
4  
5 Iruela-Arispe ML, Chang CP. 2008a. Endocardial Brg1 represses ADAMTS1 to maintain  
6  
7 the microenvironment for myocardial morphogenesis. *Dev Cell* 14: 298-311.  
8  
9  
10 Stankunas K, Shang C, Twu KY, Kao SC, Jenkins NA, Copeland NG, Sanyal M, Selleri L,  
11  
12 Cleary ML, Chang CP. 2008b. Pbx/Meis deficiencies demonstrate multigenetic origins of  
13  
14 congenital heart disease. *Circ Res* 103: 702-709.  
15  
16  
17 Takeda M, Briggs LE, Wakimoto H, Marks MH, Warren SA, Lu JT, Weinberg EO,  
18  
19 Robertson KD, Chien KR, Kasahara H. 2009. Slow progressive conduction and contraction  
20  
21 defects in loss of Nkx2-5 mice after cardiomyocyte terminal differentiation. *Lab Invest* 89:  
22  
23 983-993.  
24  
25  
26  
27 Targoff KL, Schell T, Yelon D. 2008. Nkx genes regulate heart tube extension and exert  
28  
29 differential effects on ventricular and atrial cell number. *Dev Biol* 322: 314-321.  
30  
31  
32 Teng G, Papavasiliou FN. 2007. Immunoglobulin somatic hypermutation. *Annu Rev Genet*  
33  
34 41: 107-120.  
35  
36  
37 Tsoutsman T, Bagnall RD, Semsarian C. 2008a. Impact of multiple gene mutations in  
38  
39 determining the severity of cardiomyopathy and heart failure. *Clin Exp Pharmacol Physiol*  
40  
41 35: 1349-1357.  
42  
43  
44 Tsoutsman T, Kelly M, Ng DC, Tan JE, Tu E, Lam L, Bogoyevitch MA, Seidman CE,  
45  
46 Seidman JG, Semsarian C. 2008b. Severe heart failure and early mortality in a double-  
47  
48 mutation mouse model of familial hypertrophic cardiomyopathy. *Circulation* 117: 1820-  
49  
50 1831.  
51  
52  
53 Vincentz JW, Barnes RM, Firulli BA, Conway SJ, Firulli AB. 2008. Cooperative interaction  
54  
55 of Nkx2.5 and Mef2c transcription factors during heart development. *Dev Dyn* 237: 3809-  
56  
57 3819.  
58  
59  
60 Wagner M, Siddiqui MA. 2007a. Signal transduction in early heart development (I):  
cardiogenic induction and heart tube formation. *Exp Biol Med (Maywood)* 232: 852-865.

- 1  
2  
3 Wagner M, Siddiqui MA. 2007b. Signal transduction in early heart development (II):  
4  
5 ventricular chamber specification, trabeculation, and heart valve formation. *Exp Biol Med*  
6  
7 232: 866-880.  
8  
9
- 10 Wang Z, Zhai W, Richardson JA, Olson EN, Meneses JJ, Firpo MT, Kang C, Skarnes WC,  
11  
12 Tjian R. 2004. Polybromo protein BAF180 functions in mammalian cardiac chamber  
13  
14 maturation. *Genes Dev* 18: 3106-3116.  
15  
16
- 17 Watanabe Y, Benson DW, Yano S, Akagi T, Yoshino M, Murray JC. 2002. Two novel  
18  
19 frameshift mutations in NKX2.5 result in novel features including visceral inversus and  
20  
21 sinus venosus type ASD. *J Med Genet* 39: 807-811.  
22  
23
- 24 Weismann CG, Gelb BD. 2007. The genetics of congenital heart disease: a review of recent  
25  
26 developments. *Curr Opin Cardiol* 22: 200-206.  
27  
28
- 29 Winston JB, Erlich JM, Green CA, Aluko A, Kaiser KA, Takematsu M, Barlow RS, Sureka  
30  
31 AO, LaPage MJ, Janss LL, Jay PY. 2010. Heterogeneity of genetic modifiers ensures  
32  
33 normal cardiac development. *Circulation* 121: 1313-1321.  
34  
35
- 36 Zhang W, Li X, Shen A, Jiao W, Guan X, Li Z. 2009a. Screening NKX2.5 mutation in a  
37  
38 sample of 230 Han Chinese children with congenital heart diseases. *Genet Test Mol*  
39  
40 *Biomarkers* 13: 159-162.  
41  
42
- 43 Zhang WM, Li XF, Ma ZY, Zhang J, Zhou SH, Li T, Shi L, Li ZZ. 2009b. GATA4 and  
44  
45 NKX2.5 gene analysis in Chinese Uygur patients with congenital heart disease. *Chin Med J*  
46  
47 *(Engl)* 122: 416-419.  
48  
49
- 50 Zhou B, von Gise A, Ma Q, Rivera-Feliciano J, Pu WT. 2008. Nkx2-5- and Isl1-expressing  
51  
52 cardiac progenitors contribute to proepicardium. *Biochem Biophys Res Commun* 375: 450-  
53  
54 453.  
55  
56
- 57 Zhu W, Shiojima I, Hiroi Y, Zou Y, Akazawa H, Mizukami M, Toko H, Yazaki Y, Nagai R,  
58  
59 Komuro I. 2000. Functional analyses of three Csx/Nkx-2.5 mutations that cause human  
60  
congenital heart disease. *J Biol Chem* 275: 35291-35296.

## Legend to Figures

**Figure 1.** Summary of germline *NKX2-5* mutations in CHD, detection frequency in sporadic or familial cases, and associated cardiac malformations.

**Figure 2.** Facts about germline *NKX2-5* mutations.

**Figure 3.** Predictions of the effect of *NKX2-5* mutations on the secondary structure of the protein. *NKX2-5* interacts with DNA through a helix-turn-helix DNA-binding motif of three alpha helices within the homeodomain (HD). The amino acids in the alpha helices are underlined and those affected by *NKX2-5* mutations are indicated by asterisks. Some *NKX2-5* mutations can lead to breakage of the structure (arrows), and thus a truncated protein. For predictions, amino acids in the Swiss Model for *NKX2-5* (P52952) (<http://swissmodel.expasy.org>) were mutated using tools contained in Swiss-PdbViewer (<http://spdbv.vital-it.ch/>), and the resulting structure viewed through Protein Explorer (<http://proteinexplorer.org>).

**Figure 4.** *NKX2-5* mutations affect conserved regions of the homeodomain. Protein modelling and identification of conserved regions were undertaken using Consurf (<http://consurf.tau.ac.il/>) and Chimera (<http://www.cgl.ucsf.edu/chimera/>).

**Table 1.** Functional Consequences of Identified *NKX2-5* Mutations in CHD: Functional Assays or Bioinformatic Analysis

Functional Consequence	Mutations***
5 truncated protein before HD	c.215_221del AGCTGGG, p.E72fs c.223_224delCG, p.P77fs c.262delG, p.A88fs c.312delG, p.D105fs c.325G>T, p.E109X
6 truncated protein within HD	c.445C>T, p.Q149X c.498_499 insC, p.E167fs c.508C>T, p.Q170X c.533C>T, p.T178M c.561G>C, p.Q187H c.564C>A, p.N188K
2 truncated protein after HD	c.592C>T, p.Q198X c.605_606delTG, p.L202fs
4 truncated protein after NK2-SD	c.701_702insTCCCT, p.A235fs c.768T>A, p.Y256X c.777C>A, p.Y259X c.792C>A, p.C264X
16 defective in functional assays* (DNA binding/transactivation activity/protein-protein interaction/ nuclear localization)	c.73C>T, p.R25C c.244T>A, p.C82S c.424C>T, p.R142C c.445C>T, p.Q149X c.508C>T, p.Q170X c.512T>C, p.L171P c.533C>T, p.T178M c.561G>C, p.Q187H c.564C>A, p.N188K c.565C>G, p.R189G c.569G>A, p.R190H c.572A>G, p.Y191C c.592C>T, p.Q198X c.656C>T, p.A219V c.777C>A, p.Y259X c.334 +1G>T
8 predicted to be damaging**	c.44A>T, p.K15I c.61G>C, p.E21Q c.65A>C, p.Q22P c.65A>G, p.Q22R c.479A>C, p.Q160P c.554G>T, p.W185L c.823C>A, p.P275T c.967G>A, p.A323T
4 predicted to be tolerated**	c.124G>C, p.A42P c.188C>T, p.A63V c.380C>A, p.A127E c.839C>T, p.P280L

\* For the functional studies, see (Kasahara et al., 2000;Kasahara and Benson, 2004;Zhu et al., 2000;Monzen et al., 2002; Inga et al., 2005; Esposito et al., 2009).


\*\* predicted by PolyPhen (<http://genetics.bwh.harvard.edu/pph/>); SIFT (<http://sift.jcvi.org/>)

\*\*\* Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence NM\_0004387.3, according to journal guidelines ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)). The initiation codon is codon 1.

**Table 2.** Detection Frequency of *NKX2-5* Germline Mutations in Congenital Heart Disease


<b>Mutation- Positive Patients</b>	<b>Patients Analyzed</b>	<b>Frequency (%)</b>	<b>Study</b>	<b>Country Study/Patients</b>
1	109	0.9	(Ikeda et al., 2002)	Japan
18	608	3.0	(McElhinney et al., 2003)	USA
2	146	1.4	(Elliott et al., 2003)	Australia, USA
0	227	0	(Hobbs et al., 2005)	USA
3	16	18.8	(Hirayama-Yamada et al., 2005)	Japan
0	205	0	(Posch et al., 2008)	Germany
1	72	1.4	(Akcaboy et al., 2008)	Turkey
2	159	1.3	(Gioli-Pereira et al., 2010)	Brazil
0	230	0	(Zhang et al., 2009a)	China
0	62	0	(Zhang et al., 2009b)	China
6	125	4.8	(Esposito et al., 2009)	Italy
0	104	0	(Hamanoue et al., 2009)	Indonesia
33	2063	2.0	Total	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Summary of germline NKX2-5 mutations in CHD, detection frequency in sporadic or familial cases, and associated cardiac malformations.  
215x189mm (300 x 300 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Facts about germline NKX2-5 mutations.  
227x188mm (300 x 300 DPI)




Predictions of the effect of NKX2-5 mutations on the secondary structure of the protein. NKX2-5 interacts with DNA through a helix-turn-helix DNA-binding motif of three alpha helices within the homeodomain (HD). The amino acids in the alpha helices are underlined and those affected by NKX2-5 mutations are indicated by asterisks. Some NKX2-5 mutations can lead to breakage of the structure (arrows), and thus a truncated protein. For predictions, amino acids in the Swiss Model for NKX2-5 (P52952) (<http://swissmodel.expasy.org>) were mutated using tools contained in Swiss-PdbViewer (<http://spdbv.vital-it.ch/>), and the resulting structure viewed through Protein Explorer (<http://proteinexplorer.org>).  
227x188mm (200 x 200 DPI)



Predictions of the effect of NKX2-5 mutations on the secondary structure of the protein. NKX2-5 interacts with DNA through a helix-turn-helix DNA-binding motif of three alpha helices within the homeodomain (HD). The amino acids in the alpha helices are underlined and those affected by NKX2-5 mutations are indicated by asterisks. Some NKX2-5 mutations can lead to breakage of the structure (arrows), and thus a truncated protein. For predictions, amino acids in the Swiss Model for NKX2-5 (P52952) (<http://swissmodel.expasy.org>) were mutated using tools contained in Swiss-PdbViewer (<http://spdbv.vital-it.ch/>), and the resulting structure viewed through Protein Explorer (<http://proteinexplorer.org>).  
227x188mm (200 x 200 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



NKX2-5 mutations affect conserved regions of the homeodomain. Protein modelling and identification of conserved regions were undertaken using Consurf (<http://consurf.tau.ac.il/>) and Chimera (<http://www.cgl.ucsf.edu/chimera/>).

187x155mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



NKX2-5 mutations affect conserved regions of the homeodomain. Protein modelling and identification of conserved regions were undertaken using Consurf (<http://consurf.tau.ac.il/>) and Chimera (<http://www.cgl.ucsf.edu/chimera/>).

187x155mm (300 x 300 DPI)





**Supp. Table S1.** Studies on *NKX2-5* Mutations Associated with Congenital Heart Disease (CHD)

Ref. No.	Authors/Year	<i>NKX2-5</i> Germline Mutation	
		present	absent
1	Schott et al., 1998	x	
2	Benson et al., 1999	x	
3	Hosoda et al., 1999	x	
4	Goldmuntz et al., 2001	x	
5	Watanabe et al., 2002	x	
6	Ikeda et al., 2002	x	
7	Gutierrez-Roelens et al., 2002	x	
8	McElhinney et al., 2003	x	
9	Elliott et al., 2003	x	
10	Kasahara and Benson, 2004	x	
11	Sarkozy et al., 2005	x	
12	Hobbs et al., 2005		x
13	Hirayama-Yamada et al., 2005	x	
14	Gutierrez-Roelens et al., 2006	x	
15	Rifai et al., 2006	x	
16	Konig et al., 2006	x	
17	Majumdar et al., 2006		x
18	Pabst et al., 2008	x	
19	Akcaboy et al., 2008	x	
20	Posch et al., 2008		x
21	Khetyar et al., 2008		x
22	Bjornstad and Leren, 2009	x	
23	Esposito et al., 2009	x	
24	Draus, Jr. et al., 2009	x	
25	Hamanoue et al., 2009		x
26	Zhang et al., 2009a		x
27	Zhang et al., 2009b		x
28	Gioli-Pereira et al., 2010	x	

**Supp. Table S2.** Summary of Published Germline *NKX2-5* Mutations in Patients with Congenital Heart Defects

No.	Mutation	Amino acid change	Gene region	Phenotypes of mutation-positive patients	Occurrence of CHD	No. of mutation-positive CHD patients	Authors	Country where study conducted
1	c.44A>T	p.K15I	TN domain	ASD II	sporadic	n = 1	McElhinney et al., 2003)	USA
2.	c.61G>C	p.E21Q	TN domain	TOF	sporadic	n = 1 ( 2 unaffected family members positive)	(Goldmuntz et al., 2001) (McElhinney et al., 2003)	USA
	c.61G>C			ASD II	familial	n = 1 (2 affected family members negative)	(Elliott et al., 2003)	Australia
3.	c.65A>C	p.Q22P	5' coding region	TOF	sporadic	n = 1	(McElhinney et al., 2003)	USA
4.	c.65A>G	p.Q22R	5' coding region	ASD II	sporadic (?)	n = 1	(Draus, Jr. et al., 2009)	USA
5.	c.73C>T	p.R25C	5' coding region	TOF, VSD conoventricular	sporadic	n = 1 (unaffected mother and 2 brothers negative)	(Benson et al., 1999)	USA
	c.73C>T			TOF	sporadic/familial	n = 3 (also detected in an affected father of a positive patient, and in 2 of 43 control)	(Goldmuntz et al., 2001)	USA
	c.73C>T			TOF, TA, IAA,HLHS	sporadic/familial	n = 7 (includes 4 TOFs Benson, Goldmuntz) 4 TOF (father of 1 TOF had VSD and also positive) 1 TA, 1 IAA and 1 HLHS	(McElhinney et al., 2003)	USA
	c.73C>T			TOF	sporadic	n = 1 (also detected in the unaffected father of	(Akcaboy et al., 2008)	Turkey

1										
2										
3										
4								patient, and 2 unrelated		
5								healthy control		
6		c.73C>T			TOF	familial		n = 1	(Gioli-Pereira et al., 2010)	Brazil
7					+PDA+right			(unaffected brother		
8					sided-aortic arch			positive, sister with VSD		
9								negative)		
10		c.73C>T			accessory	sporadic,		n=4	(Esposito et al., 2009)	Italy
11					atrioventricular	familial		(unaffected parents		
12					connection			positive)		
13	6.	(c.124G>C)**	p.A42P	5' coding	Ebstein's	sporadic		n = 1	(Gioli-Pereira et al., 2010)	Brazil
14				region	anomaly			(unaffected father		
15								positive)		
16	7.	c.188C>T	p.A63V	5' coding	L-TGA	sporadic		n = 1	(McElhinney et al., 2003)	USA
17				region						
18										
19	8.	c.215_221del AGCTGGG	p.E72fs	5' coding	AV block, ASD	familial		n = 5	(Watanabe et al., 2002)	Japan
20				region	(3 sinus venosus			(4 AV block + ASD; 1		
21					type)			AF)		
22										
23										
24										
25	9.	c.223_224delCG	p. R75fs	5' coding	AV block,	familial		n = 4	(Watanabe et al., 2002)	Japan
26			(p.P77fs)**	region	ASD II			(3 AV block +ASD II,		
27								1 AV block)		
28	10.	c.244T>A	p.C82S	5' coding	accessory	sporadic		n=1	(Esposito et al., 2009)	Italy
29				region	atrioventricular					
30					connection					
31	11.	c.262delG	p.A88fs	5' coding	AV block,	familial		n = 4	(Hirayama-	Japan
32				region	ASD II			(3 AV block +ASD II	Yamada et al.,	
33								1 AV block without	2005)	
34								cardiac malformation)		
35	12.	c.312delG	p.K104fs	5' coding	AV block,	familial		n = 2	(Konig et al., 2006)	Germany
36			(p.D105fs)**	region	ASD II			(both AV block + ASD II)		
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										
47										

13.	c.325G>T	p.E109X	5' coding region	AV block, associated with ASD II, PAS, PFO, VSD	familial	n = 5 (all with AV block +ASD II, plus other defects: 2 PFO, 1 PAS, 1 VSD)	(Pabst et al., 2008)	Germany
14.	c.380C>A	p.A127E	5' coding region	ASD II	familial	n = 1 (grandfather with bileaflet aortic valve and also positive)	(McElhinney et al., 2003)	USA
15.	c.424C>T	p.R142C	HD	AV block, ASD II, PS, VSD, TOF	familial	n = 13 (positive members principally had AV block and ASD II)	(Gutierrez-Roelens et al., 2002)	Belgium
16.	c.445C>T	p.Q149X	HD	AV block, ASD II, VSD	familial	n = 6 (5 AV block, 4 ASD, 1 VSD cono-ventricular associated with TOF, and 2 VSD muscular )	(Benson et al., 1999)	USA
	c.445C>T	p.Q149X	HD	AV block, ASD II	familial	n = 7 (AV block+ ASD II)	(Bjornstad and Leren, 2009)	Norway
17.	(c.479A>C)**	p.Q160P	HD	AV block, ASD II (ASD within the oval fossa)	familial	n = 4 (all with AV block+ ASD II)	(Rifai et al., 2006)	Morocco
18.	c.498_499insC	p.E167fs	HD	AV block, ASD II	sporadic	n = 1 (parents unaffected)	(Sarkozy et al., 2005)	Italy
19.	c.508C>T	p.Q170X	HD	AV block, ASD II	familial	n = 4 (4 AV block, 2 ASD II)	(Schott et al., 1998)	USA
20.	c.512T>C	p.L171P	HD	AV block, ASD II, VSD	familial	n = 9 (all with AV block, and	(Kasahara and Benson, 2004)	USA

7 with ASD, 1 VSD)

1									
2									
3									
4									
5	21.	c.533C>T	p.T178M	HD	AV block, ASD II	familial	n = 12 (2 families; 12 AV block, 11 ASD II)	(Schott et al., 1998)	USA
6									
7									
8		c.533C>T			AV block, ASD II, atrial fibrillation (AF)	familial	n = 2 1 AV block+ASD II, 1 ASD II+AF)	(Hirayama- Yamada et al., 2005)	Japan
9									
10		c.533C>T			ASD II, HLHS	familial	n = 3 (1 phenotypically normal family member also positive; 1 ASD II +HLHS, 2 ASD II)	(Elliott et al., 2003)	Australia
11									
12									
13									
14									
15									
16									
17	22.	c.554G>T	p.W185L	HD	AV block, ASD II, VSD	familial	n = 3 (1 AV block +ASD II, 2 ASD II+ muscular VSD (swiss-cheese VSD)	(Sarkozy et al., 2005)	Italy
18									
19									
20									
21	23.	c.561G>C	p.Q187H	HD	AV block, ASD II, anomalous systemic venous return	familial	n = 6 (2 positive members had anomalous venous return)	(Gutierrez- Roelens et al., 2002)	Belgium
22									
23									
24									
25									
26									
27									
28									
29	24.	c.564C>A	p.N188K	HD	AV block, ASD II, abnormal tricuspid valve, reduced LV function	familial	n = 5 ( 5 AV block, 5 ASD II, 3 abnormal TV, 1 reduced LV function )	(Benson et al., 1999)	USA
30									
31									
32									
33									
34									
35	25.	c.565C>G	p.R189G	HD	AV block, ASD II abnormal tricuspid valve, reduced LV function	familial	n = 5 (5 AV block ), 4 ASD, 1 abnormal TV, 3 reduced LV function	(Benson et al., 1999)	USA
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									

1									
2									
3	26.	c.568C>T	p.R190C	HD	AV block, ASD II (cribriform type)	familial	n = 1	(Hirayama- Yamada et al., 2005)	Japan
4									
5									
6									
7									
8	27.	c.569G>A	p.R190H	HD	AV block, ASD II	familial	n = 3 (3 AV block +ASD I, 2 with VSD)	(Kasahara and Benson, 2004)	USA
9									
10									
11									
12	28.	c.572A>G	p.Y191C	HD	AV block, ASD II, VSD conoventricular	familial	n = 1 (parents and siblings negative)	(Benson et al., 1999)	USA
13									
14									
15									
16									
17	29.	c.592C>T	p.Q198X	3' coding region	AV block, ASD II	familial	n = 3	(Schott et al., 1998)	USA
18		c.592C>T			AV block, ASD II	familial	n = 1	(Hosoda et al., 1999)	Japan
19									
20	30.	c.605_606delTG	p.L202fs	3' coding region	AV block, ASD II VSD	familial	n = 3 (2 AV block +ASD; 1 AV block+ASD+VSD)	(Sarkozy et al., 2005)	Italy
21									
22									
23	31.	c.646C>T	p.R216C	NK domain	TOF	sporadic	n = 1	(Goldmuntz et al., 2001) (McElhinney et al., 2003)	USA
24									
25									
26									
27									
28	32.	c.656C>T	p.A219V	NK domain	TOF	sporadic	n = 1 (unaffected mother positive)	(Goldmuntz et al., 2001) (McElhinney et al., 2003)	USA
29									
30									
31									
32									
33	33.	InsTCCCT701 (c.701_702insTCCCT)**	D235AFSter (p.A235fs)**	3' coding region	AV block, ASD II	sporadic	n = 1	(McElhinney et al., 2003)	USA
34									
35									
36	34.	c.768T>A	p.Y256X	3' coding region	AV block, ASD II, AF, ventricular arrhythmias	familial	n = 5 (5 AV block, 1 ASD II + mitral valve prolapse, 1 ASD II)	(Gutierrez- Roelens et al., 2006)	Belgium
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									

35.	c.777C>A	p.Y259X	3' coding region	AV block, ASD II VSD conoventricular, VSD muscular	familial	n = 7 (7 AV Block, 6 ASD, 2 VSD conoventricular, and 1 VSD muscular)	(Benson et al., 1999)	USA
36.	(c.792C>A)**	p.C264X	3' coding region	AV block, ASD II	familial	n = 1	(Ikeda et al., 2002)	Japan
37.	c.823C>A	p.P275T	3' coding region	CoA	sporadic	n = 1	(McElhinney et al., 2003)	USA
38.	c.839C>T	p.P280L	3' coding region	accessory atrioventricular connection	sporadic	n = 1	(Esposito et al., 2009)	Italy
39.	delAAC871 (c.871_873delAAC)**	del291N (p.N291del)**	3' coding region	DORV	sporadic	n = 1	(McElhinney et al., 2003)	USA
40.	c.967G>A	p.A323T	3' coding region	TOF	sporadic	n = 1	(McElhinney et al., 2003)	USA
41.	Int1 DSG+1T (c.334+1G>T)		intronic, splice donor site	AV block	sporadic	n = 1	(Benson et al., 1999)	USA

\*\* supplied based on description in the paper or written in accordance with recommended mutation nomenclature. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence NM\_0004387.3, according to journal guidelines ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)). The initiation codon is codon 1.

Watanabe et al 2002: c.223\_224delCG (p.P77fs because p.P77 is the first aa to be affected by the frameshift, p.A76 is silent change)

Koenig et al, 2006: c.312delG (p.D105fs because p.D105 is the first aa to be affected by the frameshift)

McElhinney et al, 2003: c.701\_702insTCCCT (p.A235fs because p.S235 is the first aa to be affected by the frameshift, p.S234 is silent change)

Benson et al. 1999: Int1 DSG+1T (intron1, splice donor site (+1) G>T), c.334 +1G>T

**Supp. Table S3.** Functional Significance of Published Germline *NKX2-5* Mutations in Patients with Congenital Heart Disease

No.	Mutation	Authors	Gene region	Function (as predicted by its location or bioinformatic analysis and functional assays)	Bioinformatic methods/assays
1	c.44A>T, p.K15I	(McElhinney et al., 2003)	TN domain	damaging	SIFT/Polyphen
2.	c.61G>C, p.E21Q	(Goldmuntz et al., 2001)/(McElhinney et al., 2003) (Elliott et al., 2003)	TN domain	alters a conserved amino acid within the TN domain, damaging	SIFT/Polyphen
3.	c.65A>C p.Q22P	(McElhinney et al., 2003)	5' coding region	damaging	SIFT/Polyphen
4.	c.65A>G p.Q22R	(Draus, Jr. et al., 2009)	5' coding region	damaging	SIFT/Polyphen
5.	c.73C>T p.R25C	(Benson et al., 1999) (Goldmuntz et al., 2001),(McElhinney et al., 2003) (Akcaboy et al., 2008) (Gioli-Pereira et al., 2010) (Esposito et al., 2009)	5' coding region	(Kasahara et al., 2000) reduced DNA binding affinity as dimer, WT + R25C increase in transactivation than in WT alone  (Esposito et al., 2009) EMSA analysis no significant reduction in DNA binding significant reduction in transactivation activity at lower concentration of protein (100 ng), but masked at higher concentration	functional assays
6.	(c.124G>C)** p.A42P	(Gioli-Pereira et al., 2010)	5' coding region	tolerated	SIFT/Polyphen
7.	c.188C>T p.A63V	(McElhinney et al., 2003)	5' coding region	tolerated	SIFT/Polyphen

1					
2					
3					
4	8.	c.215_221del AGCTGGG p.E72fs	(Watanabe et al., 2002)	5' coding region	truncated protein affecting HD, NK-SD
5					
6					
7					
8					
9	9.	c.223_224delCG p.R75fs (p.P77fs)**	(Watanabe et al., 2002)	5' coding region	truncated protein affecting HD, NK-SD
10					
11					
12					
13	10.	c.244T>A p.C82S	(Esposito et al., 2009)	5' coding region	EMSA analysis no significant reduction in DNA binding significant reduction in transactivation activity at lower concentration of protein (100 ng), but masked at higher concentration
14					functional assay
15					
16					
17					
18					
19					Note: according to authors not conclusive!
20					
21	11.	c.262delG p.A88fs	(Hirayama-Yamada et al., 2005)	5' coding region	truncated protein affecting HD, NK-SD
22					
23					
24					
25	12.	c.312delG p.K104fs (p.D105fs)**	(Konig et al., 2006)	5' coding region	truncated protein affecting HD, NK-SD
26					
27					
28					
29					
30	13.	c.325G>T p.E109X	(Pabst et al., 2008)	5' coding region	truncated protein affecting HD, NK-SD
31					
32					
33	14.	c.380C>A p.A127E	(McElhinney et al., 2003)	5' coding region	tolerated
34					SIFT/Polyphen
35					
36	15.	c.424C>T p.R142C	(Gutierrez-Roelens et al., 2006)	HD	(Kasahara and Benson, 2004) reduced DNA binding, reduced transactivation, reduced interaction with NKX2-5, GATA4 and TBX5
37					functional assay, ConSurf
38					
39	16.	c.445C>T p.Q149X	(Benson et al., 1999) (Bjornstad and Leren,	HD	(Kasahara et al., 2000) no DNA binding and transactivation
40					functional assay
41					
42					
43					
44					
45					
46					
47					

1							
2							
3							
4	17.	(c.479A>C)** p.Q160P	2009) (Rifai et al., 2006)	HD	damaging	SIFT/Polyphen	
5	6						
7	8	18.	c.498_499 insC p.E167fs	(Sarkozy et al., 2005)	HD	truncated protein affecting HD, NK-SD	
9	10	19.	c.508C>T p.Q170X	(Schott et al., 1998)	HD	(Kasahara et al., 2000) no DNA binding, no transactivation, inhibited transcriptional activity of NKX2-5 WT (WT + Q170X less transactivation than in WT alone) (Zhu et al., 2000) loss of transactivation, WT + Q170X less transactivation than in WT alone, no DNA binding, diffused localization in nucleus and cytoplasm, inhibited synergistic NKX2-5-GATA4 interaction (Monzen et al., 2002) reduced expression and transactivation of cardiac-specific genes, inhibited cardiomyocyte differentiation, promoted stress-induced cell death of cardiomyocytes	functional assay/ in vitro cardiomyocyte differentiation system
11	12						
13	14	20.	c.512T>C p.L171P	(Kasahara and Benson, 2004)	HD	(Kasahara and Benson, 2004) anomalous nuclear localization, reduced DNA-protein binding reduced transactivation, less efficient interaction with GATA4 and TBX5	functional assay
15	16						
17	18	21.	c.533C>T p.T178M	(Schott et al., 1998) (Hirayama-Yamada et al., 2005) (Elliott et al., 2003)	HD	(Kasahara et al., 2000), markedly reduced DNA binding and transactivation  (Zhu et al., 2000) reduced transactivation, inhibited transcriptional activity of NKX2-5 WT (WT + T178M less transactivation than in WT alone, reduced DNA binding), inhibited NKX2-5-GATA4 synergistic interaction	functional assay/ in vitro cardiomyocyte differentiation system
19	20						
21	22						
23	24						
25	26						
27	28						
29	30						
31	32						
33	34						
35	36						
37	38						
39	40						
41	42						
43	44						
45	46						
47							

1						
2						
3				(Monzen et al., 2002)		
4				reduced expression and transactivation of cardiac-specific genes,		
5				inhibited cardiomyocyte differentiation, promoted stress-induced		
6				cell death of cardiomyocytes		
7						
8						
9				(Kasahara and Benson, 2004), anomalous nuclear localization, less		
10				repressor activity than GAL4-NKX2-5_WT (repressor)		
11						
12				(Inga et al., 2005)		
13				loss-of-function mutant in yeast assay		
14						
15	22.	c.554G>T	(Sarkozy et al., 2005)	HD	damaging	SIFT/Polyphen
16		p.W185L				
17						
18	23.	c.561G>C	(Gutierrez-Roelens et	HD	(Kasahara and Benson, 2004)	functional assay
19		p.Q187H	al., 2002)		reduced DNA binding, reduced transactivation, reduced	
20					interaction with TBX5	
21						
22	24.	c.564C>A	(Benson et al., 1999)	HD	(Kasahara et al., 2000)	functional assay
23		p.N188K			markedly reduced DNA binding and transactivation	
24					(Kasahara and Benson, 2004)	
25					less repressor activity than GAL4-NKX2-5_WT (repressor)	
26						
27						
28	25.	c.565C>G	(Benson et al., 1999)	HD	(Kasahara et al., 2000)	functional assay
29		p.R189G			markedly reduced DNA binding and transactivation, inhibited	
30					transcriptional activity of NKX2-5 WT (WT + R189G much less	
31					transactivation than in WT alone)	
32					(Kasahara and Benson, 2004) anomalous nuclear localization	
33	26.	c.568C>T	(Hirayama-Yamada	HD	damaging	SIFT/Polyphen
34		p.R190C	et al., 2005)			
35						
36						
37	27.	c.569G>A	(Kasahara and	HD	(Kasahara and Benson, 2004)	functional assay
38		p.R190H	Benson, 2004)		compartmentalized instead of diffused nuclear localization as in	
39					wt, reduced DNA binding, reduced transactivation, reduced	
40					interaction with NKX2-5, GATA4 and TBX5	
41						
42						
43						
44						
45						
46						
47						

1						
2						
3						
4	28.	c.572A>G p.Y191C	(Benson et al., 1999)	HD	(Kasahara et al., 2000),(Kasahara and Benson, 2004) markedly reduced DNA binding and transactivation, inhibited transcriptional activity of NKX2-5 WT (WT + Y191C less transactivation than in WT alone)	functional assay
5						
6						
7						
8						
9						
10	29.	c.592C>T p.Q198X	(Schott et al., 1998) (Hosoda et al., 1999)	3' coding region	(Kasahara et al., 2000) reduced DNA binding affinity as dimer (Zhu et al., 2000) reduced transactivation, WT + Q198X much increased transactivation than in WT alone, enhanced NKX2-5-GATA4 synergistic interaction, overexpression in cultured cardiomyocytes induced apoptosis (Monzen et al., 2002) lower cardiomyocyte differentiation efficiency, promoted stress- induced cell death of cardiomyocytes	functional assay / in vitro cardiomyocyte differentiation system
11						
12						
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23	30.	c.605_606delTG p.L202fs	(Sarkozy et al., 2005)	3' coding region	truncated protein leading to deletion of NK-SD	
24						
25						
26	31.	c.646C>T p.R216C	(Goldmuntz et al., 2001),(McElhinney et al., 2003)	NK2-SD domain	damaging	SIFT/Polyphen
27						
28						
29						
30	32.	c.656C>T pA219V	(Goldmuntz et al., 2001),(McElhinney et al., 2003)	NK2-SD domain	(Inga et al., 2005) reduced-function mutant in yeast assay	functional assay
31						
32						
33						
34	33.	InsTCCCT701 (c.701_702insTCCCT) ** D235AFSter (p.A235fs)**	(McElhinney et al., 2003)	3' coding region	truncated protein	
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						

1					
2					
3	34.	c.768T>A p.Y256X	(Gutierrez-Roelens et al., 2006)	3' coding region	truncated protein with 68 aa lacking, predicted to affect ability of NKX2-5 to form dimers
4					
5					
6	35.	c.777C>A p.Y259X	(Benson et al., 1999)	3' coding region	(Kasahara et al., 2000) functional assay
7					
8					
9					
10					
11	36.	(c.792C>A)** p.C264X	(Ikeda et al., 2002)	3' coding region	truncated protein
12					
13	37.	c.823C>A p.P275T	(McElhinney et al., 2003)	3' coding region	damaging SIFT/Polyphen
14					
15					
16	38.	c.839C>T p.P280L	(Esposito et al., 2009)	3' coding region	tolerated SIFT/Polyphen
17					
18	39.	delAAC871 (c.871_873del AAC)** del291N (p.N291del)**	(McElhinney et al., 2003)	3' coding region	deleted amino acid
19					
20					
21					
22					
23	40.	c.967G>A p.A323T	(McElhinney et al., 2003)	3' coding region	damaging/tolerated SIFT/Polyphen
24					
25					
26					
27	41.	Int1 DSG+1T (c.334 +1G>T)	(Benson et al., 1999)	intronic, splice donor site	(Kasahara et al., 2000) functional assay abolished intron splicing, poor accumulation of mutant protein in the cell, no DNA binding, and transactivation
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					

\*\*supplied based on description in the paper or written in accordance with recommended mutation nomenclature. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence NM\_0004387.3, according to journal guidelines ([www.hgvs.org/mutomen](http://www.hgvs.org/mutomen)). The initiation codon is codon 1.